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Approximately 20% of people with cirrhosis develop ascites. Several different treatments are available; including, among others,
 
paracentesis plus fluid replacement, transjugular intrahepatic portosystemic shunts, aldosterone antagonists, and loop diuretics.
 




To compare the benefits and harms of different treatments for ascites in people with decompensated liver cirrhosis through a network
 




We searched CENTRAL, MEDLINE, Embase, Science Citation Index Expanded, World Health Organization International Clinical Trials
 




We included only randomised clinical trials (irrespective of language, blinding, or status) in adults with cirrhosis and ascites. We excluded
 
randomised clinical trials in which participants had previously undergone liver transplantation.
 
Data collection and analysis
 
We performed a network meta­analysis with OpenBUGS using Bayesian methods and calculated the odds ratio, rate ratio, and hazard ratio
 
(HR) with 95% credible intervals (CrI) based on an available­case analysis, according to National Institute of Health and Care Excellence
 
Decision Support Unit guidance.
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We included a total of 49 randomised clinical trials (3521 participants) in the review. Forty­two trials (2870 participants) were included in
 
one or more outcomes in the review. The trials that provided the information included people with cirrhosis due to varied aetiologies,
 
without other features of decompensation, having mainly grade 3 (severe), recurrent, or refractory ascites. The follow­up in the trials
 
ranged from 0.1 to 84 months. All the trials were at high risk of bias, and the overall certainty of evidence was low or very low.
 
Approximately 36.8% of participants who received paracentesis plus fluid replacement (reference group, the current standard treatment)
 
died within 11 months. There was no evidence of differences in mortality, adverse events, or liver transplantation in people receiving
 
different interventions compared to paracentesis plus fluid replacement (very low­certainty evidence). Resolution of ascites at maximal
 
follow­up was higher with transjugular intrahepatic portosystemic shunt (HR 9.44; 95% CrI 1.93 to 62.68) and adding aldosterone
 
antagonists to paracentesis plus fluid replacement (HR 30.63; 95% CrI 5.06 to 692.98) compared to paracentesis plus fluid replacement (very
 
low­certainty evidence). Aldosterone antagonists plus loop diuretics had a higher rate of other decompensation events such as hepatic
 
encephalopathy, hepatorenal syndrome, and variceal bleeding compared to paracentesis plus fluid replacement (rate ratio 2.04; 95% CrI
 
1.37 to 3.10) (very low­certainty evidence).
 
None of the trials using paracentesis plus fluid replacement reported health­related quality of life or symptomatic recovery from ascites.
 
Funding: the source of funding for four trials were industries which would benefit from the results of the study; 24 trials received no
 




Based on very low­certainty evidence, there is considerable uncertainty about whether interventions for ascites in people with
 
decompensated liver cirrhosis decrease mortality, adverse events, or liver transplantation compared to paracentesis plus fluid
 
replacement in people with decompensated liver cirrhosis and ascites. Based on very low­certainty evidence, transjugular intrahepatic
 
portosystemic shunt and adding aldosterone antagonists to paracentesis plus fluid replacement may increase the resolution of ascites
 
compared to paracentesis plus fluid replacement. Based on very low­certainty evidence, aldosterone antagonists plus loop diuretics may
 




Treatments for ascites in people with advanced liver disease
 
What is the aim of this Cochrane review?
 
To find out the best available treatment for ascites (abnormal build­up of fluid in the tummy) in people with advanced liver disease (liver
 
cirrhosis, or late­stage scarring of the liver with complications). People with cirrhosis and ascites are at significant risk of death. Therefore,
 
it is important to treat such people, but the benefits and harms of different treatments available are currently unclear. The authors of this
 
review collected and analysed all relevant research studies with the aim of finding what the best treatment is. They found 49 randomised
 
controlled trials (studies where participants are randomly assigned to one of two treatment groups). During analysis of data, authors used
 
standard Cochrane methods, which allow comparison of only two treatments at a time. Authors also used advanced techniques that allow
 
comparison of multiple treatments simultaneously (usually referred as 'network (or indirect) meta­analysis').
 






None of the studies were conducted without flaws, and because of this, there is very high uncertainty in the findings. Approximately one
 
in three trial participants with cirrhosis and ascites who received the standard treatment of drainage of fluid (paracentesis) plus fluid
 
replacement died within 11 months of treatment. The funding source for the research was unclear in 21 studies; commercial organisations
 
funded four studies. There were no concerns regarding the source of funding for the remaining 24 trials.
 
What was studied in the review?
 
This review looked at adults of any sex, age, and ethnic origin, with advanced liver disease due to various causes and ascites. Participants
 
were given different treatments for ascites. The authors excluded studies in people who had previously had liver transplantation. The
 
average age of participants, when reported, ranged from 43 to 64 years. The treatments used in the trials included paracentesis plus fluid
 
replacement (currently considered the standard treatment), different classes of diuretics (drugs which increase the passing of urine), and
 
transjugular intrahepatic portosystemic shunt (an artificial channel that connects the different blood vessels that carry oxygen­depleted
 
blood (venous system)) within the liver to reduce the pressure built­up in the portal venous system, one of the two venous systems draining
 
the liver. The review authors wanted to gather and analyse data on death (percentage dead at maximal follow­up), quality of life, serious
 




What were the main results of the review?
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Library Better health. Cochrane Database of Systematic Reviews
 
The 49 studies included a small number of participants (3521 participants). Study data were sparse. Forty­two studies with 2870
 
participants provided data for analyses. The follow­up of the trial participants ranged from less than a week to seven years. The review
 
shows that there is low­ or very low­certainty evidence for the following:
 
­ Approximately one in three people with cirrhosis and ascites who received the standard treatment of drainage of fluid (paracentesis) plus
 
fluid replacement died within 11 months.
 












­ Using aldosterone antagonists plus loop diuretics (another class of diuretics) as a substitute for paracentesis plus fluid replacement may
 
double the development of other liver complications of cirrhosis.
 
­ None of the trials that compared other treatments to paracentesis plus fluid replacement reported health­related quality of life or
 
symptomatic recovery from ascites.
 
­ Future well designed trials are needed to find out the best treatment for people with cirrhosis and ascites.
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Summary of findings for the main comparison.
 




























































































































































Follow­up period: 0.1 to 84 months
 


















(0.70 to 1.69) 
Network estimate 
18 more per 
1000 
(109 fewer to 253 
more) 
HR 1.64 235 more per 
(0.46 to 6.32) 1000 
Network esti­ (200 fewer to 
mate 632 more) 
HR 1.24 88 more 
(0.62 to per 1000 
2.59) (141 few­
Network er to 587 
estimate more) 
HR 0.84 59 fewer per 
(0.60 to 1.18) 1000 
Network esti­ (148 fewer to 65 
mate more) 
Very low1,2,3 Very low1,2,3 Very low1,2,3 Very low1,2,3 
Based on 211 participants (4 RCTs) Based on 165 participants (5 RCTs) No direct RCT Based on 452 participants (7 RCTs) 






Rate ratio 1.30 
(0.27 to 6.99) 
Direct estimate 
Not estimable ­ ­ Not estimable 
(10 serious adverse events in 35 
participants) 
Very low1,2,3 
Based on 70 participants (1 RCT) 
Very low1,2,3 
Based on 41 participants (1 RCT) 

































                   


















                   



















































































Paracentesis plus OR 3.54 182 more per 
fluid replacement (0.43 to 27.41) 1000 
100 per 1000 Network estimate (54 fewer to 653 
(10%) more) 
Very low1,2,3 
Based on 84 participants (2 RCTs) 
Any adverse events (number of events) 
Paracentesis plus Rate ratio 4.12 367 more per 
fluid replacement (0.87 to 34.02) 1000 










Resolution of ascites at maximal follow­up (by ultrasound) 
Paracentesis plus HR 1.10 16 more per 
fluid replacement (0.12 to 10.74) 1000 
158 per 1000 Network estimate (140 fewer to 842 
(15.8%) more) 
Very low1,2,3,4 
Based on 125 participants (3 RCTs) 
OR 1.63 53 more per ­
(0.30 to 11.66) 1000 
Network esti­ (68 fewer to 464 
mate more) 
Very low1,2,3 
Based on 145 participants (4 RCTs) 
Rate ratio 1.37 43 more per ­
(0.36 to 5.82) 1000 
Network esti­ (76 fewer to 567 
mate more) 
Very low1,2,3 
Based on 25 participants (1 RCT) 
HR 1.08 10 more per ­
(0.11 to 10.35) 1000 
Network esti­ (108 fewer to 
mate 879 more) 
Very low1,2,3 
Based on 145 participants (4 RCTs) 
­ HR 1.17 27 more 
(0.01 to per 1000 
98.79) (156 few­
Network er to 842 
estimate more) 
Very low1,2,3,4 




(0.52 to 1.44) 1000 
Network esti­ (58 fewer to 54 
mate more) 
Very low1,2,3 
Based on 427 participants (6 RCT) 
HR 9.44 842 more per 
(1.93 to 62.68) 1000 
Network esti­ (147 more to 
mate 842 more) 
Very low1,2,4 































































































































       
                                 
                     
         
                                   
                                                           
                                           
                                                 
                                     
                   
                             
                     
 
 
                                       
                                             
                                           










































































































































































Rate ratio 2.04 
(1.37 to 3.10) 
Network estimate 
458 more per 
1000 
(164 more to 922 
more) 
Rate ratio 0.76 107 fewer per 
(0.14 to 3.61) 1000 
Network esti­ (377 fewer to 
mate 1144 more) 
Rate ratio 16 more 
1.04 per 1000 
(0.56 to (195 few­
1.93) er to 409 
Network more) 
estimate 
Rate ratio 1.17 76 more per 
(0.92 to 1.49) 1000 
Network esti­ (33 fewer to 217 
mate more) 
Very low1,2,4 Very low1,2,3,4 Very low1,2,3,4 Very low1,2,3,4 
Based on 242 participants (4 RCTs) Based on 114 participants (3 RCTs) No direct RCT Based on 452 participants (7 RCTs) 




GRADE Working Group grades of evidence
 
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
 




Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
 
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
 
1Downgraded one level for risk of bias because the trial(s) included in the analysis was/were at high risk of bias
 
2Downgraded one level for imprecision because the sample size was small
 
3Downgraded one level for imprecision because the credible intervals were wide (included clinical benefit and harms)
 
4Downgraded one level for inconsistency because there was evidence of statistical heterogeneity
 
Figure 1. A high resolution version of this image can be found at: https://doi.org/10.5281/zenodo.3604788.. The network plots showing the outcomes
 
for which network meta­analysis was performed. The size of the node (circle) provides a measure of the number of trials in which the particular
 
Intervention was included as one of the intervention groups. The thickness of the line provides a measure of the number of direct comparisons
 




AldoAnt = Aldosterone antagonists
 
Fluid = Fluid replacement
 
LoopD = Loop diuretics
 
No active treatment = No active treatment
 










































































































Vasodil = Systemic vasodilator
 












































































































































































































































































































               
       
       
     
   
             
     
       
 
             
     






























































































































































Summary of findings 2.
 










Follow­up period: 0.1 to 84 months
 

















(4 RCTs; 211 participants) 
HR 1.05 
(0.70 to 1.69) 
Network estimate 
368 per 1000 387 per 1000 18 more per 1000 
(260 to 621) (109 fewer to 253 more) 
Very low1,2,3 
Paracentesis plus systemic vasoconstrictors 
(5 RCTs; 165 participants) 
HR 1.64 
(0.46 to 6.32) 
Network estimate 
368 per 1000 604 per 1000 235 more per 1000 




























       
     
       
 
     
               
 
           
     
       
 
 
                   
 
                     
 
   
       
     
       
 
   
               
 
   
               
 
           
     
       
 
   
       
     
       
 












(No direct RCT) 
HR 1.24 
(0.62 to 2.59) 
Network estimate 
368 per 1000 457 per 1000 
(227 to 955) 
88 more per 1000 




(7 RCTs; 452 participants) 
HR 0.84 
(0.60 to 1.18) 
Network estimate 
368 per 1000 309 per 1000 
(221 to 433) 
59 fewer per 1000 





















































































































































(0.46 to 6.99) 
Network estimate 
368 per 1000No active treatment
 611 per 1000 243 more per 1000 Very low1,2,3
 
(No direct RCT)
 (170 to 1000) (199 fewer to 632 more)
 
Loop diuretics 
(No direct RCT) 
HR 0.71 
(0.23 to 2.16) 
Network estimate 
368 per 1000 263 per 1000 
(84 to 797) 
105 fewer per 1000 
(284 fewer to 429 more) 
Very low1,2,3 
Paracentesis plus reinfusion 
(1 RCT; 24 participants) 
HR 0.77 
(0.23 to 2.68) 
Network estimate 
368 per 1000 284 per 1000 
(84 to 987) 
84 fewer per 1000 
(285 fewer to 619 more) 
Very low1,2,3 
HR 1.06 
(0.57 to 2.16) 
Network estimate 
368 per 1000Aldosterone antagonists plus loop diuretics
 392 per 1000 23 more per 1000 Very low1,2,3
 
plus albumin




Aldosterone antagonists plus loop diuretics HR 0.97 368 per 1000 358 per 1000 10 fewer per 1000 Very low1,2,3
 
plus peritoneovenous shunt (0.40 to 2.43)
 (148 to 894) (221 fewer to 526 more)
 
(No direct RCT) Network estimate
 
HR 0.42 






153 per 1000 215 fewer per 1000 Very low1,2,3
 





(No direct RCT) 
HR 1.92 
(0.24 to 20.64) 
368 per 1000 708 per 1000 
(90 to 1000) 
340 more per 1000 










408 per 1000 40 more per 1000 Very low1,2,3
 






Aldosterone antagonists plus loop diuretics HR 0.61 368 per 1000 226 per 1000 142 fewer per 1000 Very low1,2,3
 
plus systemic vasoconstrictors plus systemic (0.02 to 9.17)
































               
 
           
     
       
 
         







         
   
     
         
             
     
       
 
             
     
       
 







































































(No direct RCT) 
Aldosterone antagonists plus loop diuretics 
plus systemic vasodilator 
(No direct RCT) 
HR 0.62 
(0.03 to 9.10) 
Network estimate 
368 per 1000 228 per 1000 140 fewer per 1000 
(12 to 1000) (357 fewer to 632 more) 
Very low1,2,3 
Systemic vasoconstrictors plus albumin 
(No direct RCT) 
HR 2.62 
(0.41 to 19.28) 
Network estimate 
368 per 1000 965 per 1000 596 more per 1000 
(151 to 1000) (218 fewer to 632 more) 
Very low1,2,3 
Serious adverse events (number of people) None of the trials with paracentesis plus fluid replacement as an intervention reported this outcome 





(1 RCT; 41 participants) 
Rate ratio 1.30 
(0.27 to 6.99) 
Direct estimate 
0 per 1000 Not estimable Very low1,2,3 
Transjugular intrahepatic portosystemic 
shunt 
(1 RCT; 70 participants) 
Not estimable 
(10 serious adverse events in 35 
participants) 
0 per 1000 Not estimable Very low1,2,3 
Health­related quality of life None of the trials with paracentesis plus fluid replacement as an intervention reported this outcome 





(4 RCTs; 145 participants) 
OR 1.63 
(0.30 to 11.66) 
Network estimate 
100 per 1000 153 per 1000 53 more per 1000 
(32 to 564) (68 fewer to 464 more) 
Very low1,2,3 
Aldosterone antagonists plus loop diuretics 
(2 RCT; 84 participants) 
OR 3.54 
(0.43 to 27.41) 
Network estimate 
100 per 1000 282 per 1000 182 more per 1000 
(46 to 753) (54 fewer to 653 more) 
Very low1,2,3 


















































































































       
     




       
     




       
     




       
     




       
     
       
 
             
     
       
 
     
               
 
             
     
       
 










































































(1 RCT; 31 participants) 
Rate ratio 4.12 
(0.87 to 34.02) 
Network estimate 
118 per 1000 485 per 1000 
(103 to 4003) 
367 more per 1000 
(15 fewer to 3885 more) 
Very low1,2,3 
Paracentesis plus systemic vasoconstrictors 
(1 RCT; 25 participants) 
Rate ratio 1.37 
(0.36 to 5.82) 
Network estimate 
118 per 1000 161 per 1000 
(42 to 685) 
43 more per 1000 




(No direct RCT) 
Rate ratio 3.30 
(0.38 to 38.51) 
Network estimate 
118 per 1000 388 per 1000 
(45 to 4531) 
271 more per 1000 





(No direct RCT) 
Rate ratio 4.25 
(0.53 to 46.99) 
Network estimate 
118 per 1000 501 per 1000 
(62 to 5529) 
383 more per 1000 




(No direct RCT) 
Rate ratio 2.41 
(0.24 to 29.67) 
Network estimate 
118 per 1000 284 per 1000 
(28 to 3490) 
166 more per 1000 







(4 RCTs; 145 participants) 
HR 1.08 
(0.11 to 10.35) 
Network estimate 
121 per 1000 131 per 1000 
(14 to 1000) 
10 more per 1000 




(6 RCTs; 427 participants) 
HR 0.87 
(0.52 to 1.44) 
Network estimate 
121 per 1000 106 per 1000 
(63 to 175) 
15 fewer per 1000 
(58 fewer to 54 more) 
Very low1,2,3 
Paracentesis plus reinfusion 
(1 RCT; 24 participants) 
HR 2.56 
(0.20 to 90.92) 
Network estimate 
121 per 1000 310 per 1000 
(25 to 1000) 
189 more per 1000 
(97 fewer to 879 more) 
Very low1,2,3 

















































































































             
             
     
       
   
       
     
       
     
       
     
       
 
                   
 
           
     
       
   
       
     
       
   
       
     
       
     
       
     
       
           












































































(3 RCTs; 125 participants) 
HR 1.10 
(0.12 to 10.74) 
Network estimate 
158 per 1000 174 per 1000 
(18 to 1000) 
16 more per 1000 





(No direct RCT) 
HR 1.17 
(0.01 to 98.79) 
Network estimate 
158 per 1000 185 per 1000 
(2 to 1000) 
27 more per 1000 





(6 RCTs; 392 participants) 
HR 9.44 
(1.93 to 62.68) 
Network estimate 
158 per 1000 1000 per 1000 
(305 to 1000) 
842 more per 1000 
(147 more to 842 more) 
Very low1,2,4 
No active treatment 
(No direct RCT) 
HR 0.16 
(0.00 to 17.37) 
Network estimate 
158 per 1000 26 per 1000 
(0 to 1000) 
132 fewer per 1000 




(No direct RCT) 
HR 2.26 
(0.01 to 846.41) 
Network estimate 
158 per 1000 357 per 1000 
(1 to 1000) 
199 more per 1000 





(No direct RCT) 
HR 3.28 
(0.09 to 118.39) 
Network estimate 
158 per 1000 517 per 1000 
(15 to 1000) 
360 more per 1000 





(No direct RCT) 
HR 8.81 
(0.06 to 1908.36) 
Network estimate 
158 per 1000 1000 per 1000 
(10 to 1000) 
842 more per 1000 





(1 RCT; 36 participants) 
HR 30.63 
(5.06 to 692.98) 
Direct estimate 
158 per 1000 1000 per 1000 
(799 to 1000) 
842 more per 1000 
(641 more to 842 more) 
Low1,2 



















































































































                     
     
   
               
   
   
       
     
       
     
   
       
     
       
   
   
       
     




               
   
   
       
     
       
   
   
               
   
   
               
   
   
               
   
   









(4 RCTs; 242 participants) (1.37 to 3.10)




Paracentesis plus systemic vasoconstrictors Rate ratio 0.76 439 per 1000 332 per 1000 107 fewer per 1000 Very
 
(3 RCTs; 114 participants) (0.14 to 3.61)






















































































































































Rate ratio 1.04 
(0.56 to 1.93) 
Network estimate 
439 per 1000Aldosterone antagonists plus loop diuretics
 455 per 1000 16 more per 1000 Very
 
plus paracentesis plus fluid replacement




Transjugular intrahepatic portosystemic Rate ratio 1.17 439 per 1000 515 per 1000 76 more per 1000 Very 
shunt (0.92 to 1.49) (405 to 655) (33 fewer to 217 more) low1,2,3,4 
(7 RCTs; 452 participants) Network estimate 
Rate ratio 3.34 
(0.85 to 13.94) 
Network estimate 
439 per 1000No active treatment
 1466 per 1000 1028 more per 1000 Very
 
(No direct RCT)
 (374 to 6115) (64 fewer to 5677 more) low1,2,3,4
 
Loop diuretics Rate ratio 0.95 439 per 1000 418 per 1000 21 fewer per 1000 Very 
(No direct RCT) (0.40 to 2.23) (176 to 977) (262 fewer to 538 more) low1,2,3,4 
Network estimate 
Rate ratio 1.56 
(0.84 to 2.87) 
Network estimate 
439 per 1000 
Rate ratio 0.84 




 682 per 1000 244 more per 1000 Very
 
plus albumin





 369 per 1000 70 fewer per 1000 Very
 
plus peritoneovenous shunt




Aldosterone antagonists plus loop diuretics Rate ratio 0.53 439 per 1000 233 per 1000 205 fewer per 1000 Very 
plus systemic vasoconstrictors (0.02 to 4.98) (7 to 2185) (431 fewer to 1747 more) low1,2,3,4 
(No direct RCT) Network estimate 
Rate ratio 0.53 
(0.02 to 4.99) 
Network estimate 
439 per 1000Aldosterone antagonists plus loop diuretics
 233 per 1000 206 fewer per 1000 Very
 
plus systemic vasoconstrictors plus systemic






Aldosterone antagonists plus loop diuretics Rate ratio 0.53 439 per 1000 231 per 1000 208 fewer per 1000 Very 
plus systemic vasodilator (0.02 to 5.11) (7 to 2241) (431 fewer to 1802 more) low1,2,3,4 





























       
     
       
                                       
         
                     
         
                                   
                                                           
                                           
                                                 
                                     
                   
                             










Systemic vasoconstrictors plus albumin Rate ratio 3.90 439 per 1000 1712 per 1000 1274 more per 1000 Very 




















































































































































*Anticipated absolute effect. Anticipated absolute effect compares two risks by calculating the difference between the risks of the intervention group with the weighted
 
median risk of the control group.
 




GRADE Working Group grades of evidence
 
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
 




Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
 
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
 
1Downgraded one level for risk of bias because the trial(s) included in the analysis was/were at high risk of bias
 
2Downgraded one level for imprecision because the sample size was small
 
3Downgraded one level for imprecision because the credible intervals were wide (includes clinical benefit and harms)
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B A C K G R O U N D its complications involve significant resources. One study reported
 




The liver is a complex organ with multiple functions including
 
carbohydrate metabolism, fat metabolism, protein metabolism,
 
drug metabolism, synthetic functions, storage functions, digestive
 
functions, excretory functions, and immunological functions (Read
 
1972). Liver cirrhosis is a liver disease in which the normal
 
microcirculation, the gross vascular anatomy, and the hepatic
 
architecture have been variably destroyed and altered with fibrous
 
septa surrounding regenerated or regenerating parenchymal
 
nodules  (Tsochatzis 2014; NCBI 2018a). The major causes of liver
 
cirrhosis include excessive alcohol consumption, viral hepatitis,
 
non­alcohol­related fatty liver disease, autoimmune liver disease,
 
and metabolic liver disease (Williams 2014; Ratib 2015; Setiawan
 
2016). The global prevalence of liver cirrhosis is difficult to estimate
 
as most estimates correspond to chronic liver disease (which
 
includes liver fibrosis and liver cirrhosis). In studies from the USA,
 
the prevalence of chronic liver disease varies between 0.3% to
 
2.1%  (Scaglione 2015; Setiawan 2016); in the UK, the prevalence
 
was 0.1% in one study (Fleming 2008). In 2010, liver cirrhosis was
 
responsible for an estimated 2% of all global deaths, equivalent
 
to one million deaths (Mokdad 2014). There is an increasing
 
trend of cirrhosis­related deaths in some countries, such as the
 
UK, while there is a decreasing trend in other countries, such
 
as France (Mokdad 2014;  Williams  2014). The major cause of
 
complications and deaths in people with liver cirrhosis is due to the
 
development of clinically significant portal hypertension (hepatic
 
venous pressure gradient at least 10 mmHg) (De Franchis 2015).
 
Some of the clinical features of decompensation include jaundice,
 
coagulopathy, ascites, variceal bleeding, hepatic encephalopathy,
 
and renal failure (De Franchis 2015; McPherson 2016; EASL 2018).
 






Ascites is accumulation of free fluid in the abdomen (peritoneal
 
cavity) (NCBI  2018b), and is a feature of liver decompensation
 
(Tsochatzis 2017). Approximately 20% of people with cirrhosis have
 
ascites (D'Amico 2014). Approximately 1% to 4% of people with
 
cirrhosis develop ascites each year (D'Amico 2006; D'Amico 2014).
 
Ascites is the first sign of liver decompensation in about a third of
 
people with compensated liver cirrhosis (D'Amico 2014). Ascites can
 
be graded as grade 1 ascites, which is mild ascites only detectable
 
by ultrasound examination; grade 2 or moderate ascites which is
 
manifested by moderate symmetrical distension of the abdomen;
 
and grade 3 ascites which is large or gross ascites with marked
 
abdominal distension (Arroyo 1996; Moore 2003). Grade 3 ascites
 
is also called 'tense' ascites (Arroyo 1996). Ascites that is refractory
 
to medical treatment is called 'refractory' ascites (Arroyo 1996;
 
Moore 2003). Table 1 provides detailed criteria for the definition of
 
refractory ascites (Moore 2003).
 
In people with cirrhosis, the onset of ascites and treatment of
 
ascites result in a decrease in health­related quality of life (Kim
 
2006;  Les 2010;  Orr  2014). Resolution of ascites may result in
 
improvement in health­related quality of life in people with ascites
 
(Orr  2014). The one­year mortality in people with liver cirrhosis
 
and ascites is 20%, which increases to 57% in those with ascites
 
and variceal bleeding (D'Amico 2006). Management of ascites and
 
that people with liver cirrhosis and ascites required on average one
 






The exact mechanism by which ascites develops in people with
 
liver cirrhosis is unknown. Portal hypertension causes arterial
 
vasodilatation of the splanchnic circulation (dilation of the blood
 
vessels supplying the digestive organs in the abdomen such as
 
liver, pancreas, and intestines) (Ginès  2009;  Moore 2013).  This
 
activates the renin–angiotensin system (Ginès 2009; Moore 2013),
 
leading to fluid retention (Moore 2013). In addition, the vessel
 
wall permeability is increased due to the pathological increase in
 
vascular endothelial growth factor (VEGF) (Colle  2008),  and  the
 
oncotic pressure is decreased due to decreased albumin synthesis
 
by the diseased liver leading to leaky splanchnic blood vessels in
 
people with portal hypertension (Moore 2013). This results in fluid
 
accumulation in the peritoneal cavity, that is, ascites (Moore 2013).
 
Description of the intervention
 
Although people with cirrhosis and grade 2 ascites, grade 3
 




cirrhotic ascites alone without other features of end­stage liver
 
disease, such as jaundice, variceal bleeding, spontaneous bacterial
 
peritonitis, or hepatorenal syndrome, are usually treated using less
 
invasive methods than liver transplantation (EASL 2010). According
 
to the European Association for the Study of the Liver (EASL)
 
and American Association for the Study of Liver Diseases (AASLD)
 
guidelines, grade 1 ascites does not require any specific treatment;
 
grade 2 requires salt­restricted diet and diuretics; and grade 3
 
requires large volume paracentesis (removal of several litres of
 




In people with diuretic­refractory ascites, paracentesis and
 
transjugular intrahepatic portosystemic shunt (TIPS) are the main
 
treatments according to EASL and AASLD guidelines (EASL  2010;
 
Runyon 2013; EASL 2018). In addition, AASLD guidelines suggests
 
that midodrine (a vasoconstrictor) should be considered in people
 
with refractory ascites (Runyon 2013), while midodrine is not
 
recommended by EASL guidelines (EASL 2018).
 
The role of vasoconstrictors, spontaneous ultrafiltration and
 
reinfusion (filter the removed ascitic fluid and reinfuse the
 
proteins), and low­flow ascites fluid pump (automatically diverts
 
ascitic fluid to the urinary bladder, from where it is excreted in
 
urine) in the treatment of people with ascites is unclear and neither
 
EASL nor AASLD guidelines recommend their routine use (EASL
 
2010;  Runyon 2013). Surgical portosystemic shunts are currently
 
recommended only in people with refractory ascites unsuitable
 




How the intervention might work
 
Diuretics increase fluid excretion, thereby decreasing the fluid
 
accumulation: fluid accumulation is one of the mechanisms of
 
developing ascites, and decreasing fluid accumulation can lead to
 
resolution of ascites. Systemic vasoconstrictor drugs decrease the
 
Treatment for ascites in adults with decompensated liver cirrhosis: a network meta­analysis (Review)
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Paracentesis involves removing the ascitic fluid. Removal of up
 
to 5 litres of fluid in one session of paracentesis is unlikely to
 
cause circulatory shock (EASL  2010;  Runyon 2013), but removal
 
of more than this volume can lead to circulatory shock. Various
 
methods to try to overcome this are to administer albumin, colloids
 
such as hydroxyethyl starch, vasoconstrictors such as midodrine,
 
or reinfusing the proteins from the ascitic fluid into systemic
 
circulation (Bruno 1992; Altman 1998; Appenrodt 2008). However,
 
the benefits of plasma expanders for people with cirrhosis and
 




TIPS procedures and other surgical forms of portosystemic shunt
 
are aimed at decreasing portal venous pressure, the major cause of
 
ascites in people with liver cirrhosis.
 
Why it is important to do this review
 
It is important to provide optimal treatment to people with
 
ascites to improve their survival and health­related quality of
 
life. Several different treatments are available, but their relative
 
efficacy and optimal combinations are not known. One Cochrane
 
Review on TIPS versus paracentesis for people with cirrhosis
 
with refractory ascites was available at the start of this project
 
(Saab 2006); however, to date, there have not been any network
 
meta­analyses on the topic. Network meta­analysis allows for a
 
combination of direct and indirect evidence and the ranking of
 
different interventions for different outcomes (Salanti 2011; Salanti
 
2012). With this systematic review and network meta­analysis, we
 
provide the best level of evidence for the benefits and harms of
 
different treatments for ascites in people with decompensated liver
 
cirrhosis. We have also presented results from direct comparisons
 






To compare the benefits and harms of different treatments for
 
ascites in people with decompensated liver cirrhosis through a
 
network meta­analysis and to generate rankings of the different
 








We considered only randomised clinical trials (including cross­over,
 
cluster­randomised clinical trials) for this network meta­analysis
 
irrespective of language, publication status, or date of publication.
 
We excluded studies of other designs because of the risk of bias
 
in such studies. Inclusion of indirect observational evidence could
 
weaken our network meta­analysis, but this could also be viewed
 
as a strength for assessing rare adverse events. It is well­established
 
that exclusion of non­randomised studies increases the focus on
 
potential benefits and reduces the focus on the risks of serious
 
adverse events and those of any adverse events. However, we did
 
not include these studies because of the findings of this review, i.e.
 






We included randomised clinical trials with adult trial participants
 
(18 years old and above) undergoing treatment for ascites
 
with decompensated liver cirrhosis. We excluded randomised
 






We included any of the following treatments for comparison with
 
one another, either alone or in combination.

•	 Diuretics (different classes of diuretics based on their
 
mechanism of action will be treated as separate interventions,
 
for example, loop diuretics such as furosemide, torsemide;
 




•	 Large volume paracentesis (removal of ascitic fluid) with
 
different fluids to prevent circulatory dysfunction (for example,
 




•	 Spontaneous ultrafiltration and reinfusion (filtering the
 
removed ascitic fluid and reinfusing the proteins);
 
•	 Low­flow ascites fluid pump (automatic diversion of ascitic fluid
 
to the urinary bladder, from where it is excreted in urine);
 
•	 Systemic vasoconstrictor (for example, terlipressin, midodrine);
 
•	 TIPS procedure (decrease in portal hypertension);
 








We considered 'paracentesis plus fluid replacement' as the
 
reference group. Each of the above categories was considered
 
as a 'treatment node'; the only exception was the diuretics,
 
where we considered different classes of diuretics as different
 
treatment nodes. We considered variations in drugs within the
 
same class of diuretics, doses of drugs, frequency and duration
 
of interventions as the same treatment node. We treated each
 




We excluded trials that evaluated co­interventions such as fluid
 
restriction, restricted­salt diet, or drugs such as vasopressin­

antagonists which are used as supplements to diuretics
 
to overcome their adverse effects such as hyponatraemia.
 
However, we included trials in which such co­interventions were
 
administered equally in both trial arms.
 
We evaluated the plausibility of the network meta­analysis
 
transitivity assumption by looking at the inclusion and exclusion
 
criteria in the studies. The transitivity assumption means
 
that participants included in the different trials with different
 
treatments (in this case, ascites) can be considered to be a part
 
of a multi­arm randomised clinical trial and could potentially
 
have been randomised to any of the interventions (Salanti 2012).
 
In other words, any participant that meets the inclusion criteria
 
is, in principle, equally likely to be randomised to any of the
 
above eligible interventions. This necessitates that information on
 
potential effect­modifiers such as grade of ascites (grade 2 ascites,
 
grade 3 ascites, or refractory ascites) are the same across trials. We
 
Treatment for ascites in adults with decompensated liver cirrhosis: a network meta­analysis (Review)
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performed separate meta­analysis for each of these different types
 
of ascites, when possible, to ensure that the concerns about the
 
transitivity assumption were minimised.
 




•	 All­cause mortality at maximal follow­up, i.e. the outcome
 




•	 Health­related quality of life using a validated scale such as the
 
EQ­5D or 36­Item Short Form Health Survey (SF­36) at maximal
 
follow­up (EuroQol 2018; Optum 2018).

•	 Serious adverse events (during or within six months after
 
cessation of the intervention). We defined a serious adverse
 
event as any event that would increase mortality; is life­

threatening; requires hospitalisation; results in persistent or
 
significant disability; is a congenital anomaly/birth defect; or
 
any important medical event that might jeopardise the person
 
or require intervention to prevent it (ICH­GCP 1997). However,
 
none of the trial authors defined serious adverse events.
 
Therefore, we used the list provided by trial authors for serious
 
adverse events (as indicated in the protocol).









•	 Any adverse events (during or within six months after cessation
 
of the intervention): We defined an adverse event as any
 
untoward medical occurrence not necessarily having a causal
 
relationship with the intervention but resulting in a dose
 
reduction or discontinuation of the intervention (any time after
 
commencement of the intervention) (ICH­GCP 1997). However,
 
none of the trial authors defined 'adverse event'. Therefore, we
 
used the list provided by trial authors for adverse events (as
 
indicated in the protocol).

*	 proportion of people with one or more adverse events;
 
*	 number of any adverse events per participant.
 
•	 Time­to­liver transplantation (maximal follow­up).
 






*	 resolution as per ultrasound.
 
















We chose the outcomes of this review based on their importance
 
to patients in a survey related to research priorities for people
 
with liver diseases (Gurusamy  2019), based on feedback of the
 
patient and public representative of this project, and based on an
 








We searched the Cochrane Central Register of Controlled Trials
 
(CENTRAL) in the Cochrane Library, MEDLINE Ovid, Embase
 
Ovid, and Science Citation Index Expanded (Web of Science)
 
from inception to date of search for randomised clinical trials
 
comparing two or more of the above interventions without
 
applying any language restrictions (Royle 2003). We searched
 
for all possible comparisons formed by the interventions of
 
interest. To identify further ongoing or completed trials, we also
 
searched clinicaltrials.gov, and the World Health Organization
 
International Clinical Trials Registry Platform (apps.who.int/
 
trialsearch/) which searches various trial registers, including
 
ISRCTN and ClinicalTrials.gov. We also searched the European
 
Medical Agency (EMA) (www.ema.europa.eu/ema/) and USA Food
 
and Drug Administration (FDA) (www.fda.gov) registries for
 
randomised clinical trials. We provided the search strategies along
 




We searched the references of the identified trials and the existing
 








Two review authors (KG and AB, DR, LP, or MP) independently
 
identified trials for inclusion by screening the titles and abstracts
 
of articles identified by the literature search, and sought full­text
 
articles of any references identified by at least one review author
 
for potential inclusion. We selected trials for inclusion based on the
 
full­text articles. We listed the references that we excluded and the
 
reasons for their exclusion in the Characteristics of excluded studies
 
table. We also listed any ongoing trials identified primarily through
 
the search of the clinical trial registers for further follow­up. We
 
resolved any discrepancies through discussion. We illustrated the
 
study selection process in a PRISMA diagram.
 
Data extraction and management
 
Two review authors (KG and AB, DR, LP, or MP) independently
 
extracted the following data onto a pre­piloted Microsoft Excel­









*	 number of participants randomised;
 
*	 number of participants included for the analysis;
 
*	 number of participants with events for binary outcomes,
 
mean and standard deviation for continuous outcomes,
 
number of events and the mean follow­up period for count
 
outcomes, and number of participants with events and the
 
mean follow­up period for time­to­event outcomes;
 
*	 natural logarithm of the hazard ratio and its standard error
 
if this was reported rather than the number of participants
 




*	 definition of outcomes or scale used, if appropriate.
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•	 Data on potential effect modifiers:

*	 participant characteristics such as age, sex, grade of ascites,
 
whether refractory or recurrent ascites, the aetiology for
 








*	 length of follow­up;
 






*	 year and language of publication;
 
*	 country in which the participants were recruited;
 
*	 year(s) in which the trial was conducted;
 
*	 inclusion and exclusion criteria.
 
We collected outcomes at maximum follow­up, but also at short­

term (up to three months) and medium­term (from three months
 
to five years) if this was available.
 
We attempted to contact the trial authors in the case of unclear
 




Assessment of risk of bias in included studies
 
We followed the guidance in the Cochrane Handbook for Systematic
 
Reviews of Interventions (Higgins  2011) to assess the risk of bias
 
in the included trials. Specifically, we assessed sources of bias as
 
defined below (Schulz  1995;  Moher  1998;  Kjaergard 2001;  Wood
 




•	 Low risk of bias: sequence generation was achieved using
 
computer random number generation or a random number
 
table. Drawing lots, tossing a coin, shuffling cards, and throwing
 
dice were adequate if performed by an independent person not
 
otherwise involved in the trial.
 




•	 High risk of bias: the sequence generation method was not
 






•	 Low risk of bias: the allocation sequence was described
 
as unknown to the investigators. Hence, the participants'
 
allocations could not have been foreseen in advance of, or
 
during, enrolment. Allocation was controlled by a central and
 
independent randomisation unit, an onsite locked computer,
 
identical­looking numbered sealed opaque envelopes, drug
 
bottles or containers prepared by an independent pharmacist,
 
or an independent investigator.
 
•	 Unclear risk of bias: it was unclear if the allocation was hidden
 
or if the block size was relatively small and fixed so that
 




•	 High risk of bias: the allocation sequence was likely to be known
 






•	 Low risk of bias: blinding of participants and key study personnel
 
ensured, and it was unlikely that the blinding could have been
 
broken; or rarely no blinding or incomplete blinding, but the
 
review authors judged that the outcome was not likely to be
 
influenced by lack of blinding.
 
•	 Unclear risk of bias: any of the following: insufficient information
 




•	 High risk of bias: any of the following: no blinding or incomplete
 
blinding, and the outcome was likely to be influenced by lack
 
of blinding; or blinding of key study participants and personnel
 
attempted, but likely that the blinding could have been broken,
 




•	 Low risk of bias: blinding of outcome assessment ensured, and
 
unlikely that the blinding could have been broken; or rarely no
 
blinding of outcome assessment, but the review authors judged
 
that the outcome measurement was not likely to be influenced
 
by lack of blinding.
 
•	 Unclear risk of bias: any of the following: insufficient information
 




•	 High risk of bias: any of the following: no blinding of outcome
 
assessment, and the outcome measurement was likely to
 
be influenced by lack of blinding; or blinding of outcome
 
assessment, but likely that the blinding could have been broken,
 






•	 Low risk of bias: missing data were unlikely to make treatment
 
effects depart from plausible values. The study used sufficient
 
methods, such as multiple imputation, to handle missing data.
 
•	 Unclear risk of bias: there was insufficient information to assess
 
whether missing data in combination with the method used to
 
handle missing data were likely to induce bias on the results.
 






•	 Low risk of bias: the trial reported the following predefined
 
outcomes: all­cause mortality, adverse events, and time to
 
resolution of ascites. If the original trial protocol was available,
 
the outcomes should have been those called for in that protocol.
 
If we obtained the trial protocol from a trial registry (e.g.
 
ClinicalTrials.gov), the outcomes sought should have been those
 
enumerated in the original protocol if the trial protocol was
 
registered before or at the time that the trial was begun. If the
 
trial protocol was registered after the trial was begun, we did not
 
consider those outcomes to be reliable.
 
•	 Unclear risk of bias: not all predefined, or clinically relevant and
 
reasonably expected, outcomes were reported fully, or it was
 
unclear whether data on these outcomes were recorded or not.
 
•	 High risk of bias: one or more predefined or clinically relevant
 
and reasonably expected outcomes were not reported, despite
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•	 Low risk of bias: the trial appeared to be free of other
 
components that could put it at risk of bias (e.g. inappropriate
 




•	 Uncertain risk of bias: the trial may or may not have been free of
 
other components that could put it at risk of bias.
 
•	 High risk of bias: there were other factors in the trial that could
 
put it at risk of bias (e.g. baseline differences, early stopping).
 
We considered a trial to be at low risk of bias if we assessed
 
the trial to be at low risk of bias across all listed bias risk
 
domains. Otherwise, we considered trials to be at high risk of
 
bias. At the outcome level, we classified an outcome to be at
 
low risk of bias if the allocation sequence generation, allocation
 
concealment, blinding of participants, healthcare professionals,
 
and outcome assessors, incomplete outcome data, and selective
 
outcome reporting (at the outcome level) were at low risk of bias
 
for objective and subjective outcomes (Savović 2018).
 




For dichotomous variables (e.g. proportion of participants with
 
serious adverse events or any adverse events), we calculated
 
the odds ratio (OR) with 95% credible interval (CrI) (or Bayesian
 
confidence interval) (Severini 1993). For continuous variables (e.g.
 
health­related quality of life reported on the same scale), we
 
calculated the mean difference (MD) with 95% Crl. We planned to
 
use standardised mean difference (SMD) values with 95% Crl for
 
health­related quality of life if included trials used different scales.
 
If we calculated the SMD, we planned to convert it to a common
 
scale, for example, EQ­5D or SF­36 (using the standard deviation
 
of the common scale) for the purpose of interpretation. For count
 
outcomes (e.g. number of serious adverse events or number of any
 
adverse events), we calculated the rate ratio (RaR) with 95% Crl.
 
This assumes that the events are independent of each other, i.e. if a
 
person has had an event, they are not at an increased risk of further
 
outcomes, which is the assumption in Poisson likelihood. For time­

to­event data (e.g. all­cause mortality at maximal follow­up), we
 




We estimated the ranking probabilities for all interventions of being
 
at each possible rank for each intervention for each outcome when
 
NMA (network meta­analysis) was performed. We obtained the
 
surface under the cumulative ranking curve (SUCRA) (cumulative
 
probability), rankogram, and relative ranking table with CrI for the
 




Unit of analysis issues
 
The unit of analysis was the participant undergoing treatment for
 






If we identified any cluster­randomised clinical trials, we planned to
 
include cluster­randomised clinical trials, provided that the effect
 
estimate adjusted for cluster correlation was available or if there
 
was sufficient information available to calculate the design effect
 
(which would allow us to take clustering into account). We also
 
planned to assess additional domains of risk of bias for cluster­

randomised trials according to guidance in the Cochrane Handbook
 
for Systematic Reviews of Interventions (Higgins 2011).
 
Cross­over randomised clinical trials
 
If we identified any cross­over randomised clinical trials, we
 
planned to include only the outcomes after the period of the first
 




Trials with multiple intervention groups
 
We collected data for all trial intervention groups that met the
 
inclusion criteria. The codes that we used for analysis accounted
 




Dealing with missing data
 
We performed an intention­to­treat analysis, whenever possible
 
(Newell 1992); otherwise, we used the data available to us. When
 
intention­to­treat analysis was not used and the data were not
 
missing at random (for example, treatment was withdrawn due to
 
adverse events or duration of treatment was shortened because
 
of lack of response and such participants were excluded from
 
analysis), this could lead to biased results; therefore, we conducted
 
best­worst case scenario analysis (assuming a good outcome in
 
the intervention group and bad outcome in the control group)
 
and worst­best case scenario analysis (assuming a bad outcome
 
in the intervention group and good outcome in the control group)
 
as sensitivity analyses, whenever possible, for binary and time­to­

event outcomes, where binomial likelihood was used.
 
For continuous outcomes, we imputed the standard deviation from
 
P values, according to guidance in the Cochrane Handbook for
 
Systematic Reviews of Interventions (Higgins 2011). If the data were
 
likely to be normally distributed, we used the median for meta­

analysis when the mean was not available; otherwise, we planned
 
to simply provide a median and interquartile range of the difference
 
in medians. If it was not possible to calculate the standard deviation
 
from the P value or the confidence intervals, we planned to impute
 
the standard deviation using the largest standard deviation in other
 
trials for that outcome. This form of imputation can decrease the
 
weight of the study for calculation of mean differences and may bias
 






We assessed clinical and methodological heterogeneity by carefully
 
examining the characteristics and design of included trials. We
 
also planned to assess the presence of clinical heterogeneity by
 
comparing effect estimates (please see Subgroup analysis and
 
investigation of heterogeneity) in trial reports of different drug
 
dosages, different grades of ascites (grade 2 or grade 3), refractory
 
or recurrent ascites, different aetiologies for cirrhosis (for example,
 
alcohol­related liver disease, viral liver diseases, autoimmune liver
 
disease), and based on the co­interventions (for example, both
 
groups receive prophylactic antibiotics to decrease the risk of
 
subacute bacterial peritonitis). Different study designs and risk of
 
bias can contribute to methodological heterogeneity.
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We assessed statistical heterogeneity by comparing the results
 
of the fixed­effect model meta­analysis and the random­effects
 
model meta­analysis, between­study standard deviation (tau2 and
 
comparing this with values reported in a study of the distribution
 
of between­study heterogeneity estimates) (Turner 2012),  and
 
by calculating the NMA­specific I2 statistic (Jackson  2014)  using
 
Stata/SE 15.1. When possible, we explored substantial clinical,
 
methodological, or statistical heterogeneity and addressed the
 




Assessment of transitivity across treatment comparisons
 
We assessed the transitivity assumption by comparing the
 
distribution of the potential effect modifiers (clinical: grade of
 
ascites (grade 2 versus grade 3) and whether refractory or recurrent
 
ascites; and methodological: risk of bias, year of randomisation,
 
duration of follow­up) across the different pairwise comparisons.
 
Assessment of reporting biases
 
For the network meta­analysis, we planned to perform a
 
comparison­adjusted funnel plot. However, to interpret a
 
comparison­adjusted funnel plot, it is necessary to rank the studies
 
in a meaningful way as asymmetry may be due to small sample
 
sizes in newer studies (comparing newer treatments with older
 
treatments) or higher risk of bias in older studies (Chaimani 2012).
 
As there was no meaningful way in which to rank these studies
 
(i.e. there was no specific change in the risk of bias in the studies,
 
sample size, or the control group used over time), we judged the
 
reporting bias by the completeness of the search (Chaimani 2012).
 






Methods for indirect and mixed comparisons
 
We conducted network meta­analyses to compare multiple
 
interventions simultaneously for each of the primary and
 
secondary outcomes. When two or more interventions were
 
combined, we considered this as a separate intervention ('node').
 
Network meta­analysis combines direct evidence within trials and
 
indirect evidence across trials (Mills 2012). We obtained a network
 
plot to ensure that the trials were connected by interventions using
 
Stata/SE 15.1 (Chaimani  2013). We excluded any trials that were
 
not connected to the network from the network meta­analysis,
 
and we reported only the direct pairwise meta­analysis for such
 
comparisons. We summarised the population and methodological
 
characteristics of the trials included in the network meta­analysis
 
in a table based on pairwise comparisons. We conducted a
 
Bayesian network meta­analysis using the Markov chain Monte
 
Carlo method in OpenBUGS 3.2.3, according to guidance from
 
the National Institute for Health and Care Excellence (NICE)
 
Decision Support Unit (DSU) documents (Dias 2016). We modelled
 
the treatment contrast (i.e. log odds ratio for binary outcomes,
 
mean difference or standardised mean difference for continuous
 
outcomes, log rate ratio for count outcomes, and log hazard ratio
 
for time­to­event outcomes) for any two interventions ('functional
 
parameters') as a function of comparisons between each individual
 
intervention and the reference group ('basic parameters') using
 
appropriate likelihood functions and links (Lu 2006).  We  used
 
binomial likelihood and logit link for binary outcomes, Poisson
 
likelihood and log link for count outcomes, binomial likelihood
 
and complementary log­log link (a semiparametric model which
 
excludes censored individuals from the denominator of ‘at risk’
 
individuals at the point when they are censored) for time­to­event
 
outcomes, and normal likelihood and identity link for continuous
 
outcomes. We used 'paracentesis plus fluid replacement' as the
 
reference group across the networks, as this was the commonest
 
intervention compared in the trials. We performed a fixed­effect
 
model and random­effects model for the network meta­analysis.
 
We reported both models for comparison with the reference group
 
in a forest plot when the results were different between the models.
 
For each pairwise comparison in a table, we reported the fixed­

effect model if the two models reported similar results; otherwise,
 
we reported the more conservative model, i.e. usually using the
 
random­effects model in the absence of ‘small­study’ bias.
 
We used a hierarchical Bayesian model using three different sets
 
of initial values to start the simulation­based parameter estimation
 
to assist with the assessment of convergence, employing codes
 
provided by NICE DSU (Dias 2016). We used a normal distribution
 
with large variance (10,000) for treatment effect priors (vague or flat
 
priors) centred at no effect. For the random­effects model, we used
 
a prior distributed uniformly (limits: 0 to 5) for the between­trial
 
standard deviation parameter and assumed this variability would
 
be the same across treatment comparisons (Dias 2016). We used a
 
'burn­in' of 30,000 simulations, checked for convergence (of effect
 
estimates and between­study heterogeneity) visually (i.e. whether
 
the values in different chains mixed very well by visualisation),
 
and ran the models for another 10,000 simulations to obtain effect
 
estimates. If we did not obtain convergence, we increased the
 
number of simulations for the 'burn­in' and used the 'thin' and
 
'over relax' functions to decrease the autocorrelation. If we still
 
did not obtain convergence, we used alternate initial values and
 
priors employing methods suggested by Van Valkenhoef 2012. We
 
estimated the probability that each intervention ranked at each of
 




We assessed inconsistency (statistical evidence of the violation
 
of the transitivity assumption) by fitting both an inconsistency
 
model and a consistency model. We used inconsistency models
 
employed in the NICE DSU manual, as we used a common between­

study standard deviation (Dias 2014). In addition, we used design­

by­treatment full interaction model and inconsistency factor (IF)
 
plots to assess inconsistency (Higgins 2012; Chaimani 2013), when
 
applicable. We used Stata/SE 15.1 to create IF plots. In the presence
 
of inconsistency, we assessed whether the inconsistency was due
 
to clinical or methodological heterogeneity by performing separate
 
analyses for each of the different subgroups mentioned in the
 
Subgroup analysis and investigation of heterogeneity or limited
 










Subgroup analysis and investigation of heterogeneity
 
We planned to assess the differences in the effect estimates
 
between the following subgroups and investigated heterogeneity
 
and inconsistency using meta­regression with the help of the codes
 
provided in NICE DSU guidance (Dias  2012a), if we included a
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sufficient number of trials (when there were at least two trials in at
 
least two of the subgroups). We planned to use the following trial­

level covariates for meta­regression.

•	 Trials at low risk of bias (risk of bias in all domains were low)
 
compared to trials at high risk of bias (risk of bias was unclear or
 
high in at least one of the domains).
 




•	 The aetiology for cirrhosis (for example, alcohol­related liver
 
disease, viral liver diseases, autoimmune liver disease).
 




•	 The co­interventions (for example, both groups received
 




•	 The period of follow­up (short­term: up to three months,
 
medium­term: more than three months to five years, long­term:
 
more than five years).
 
•	 The definition used by authors for serious adverse events
 




We calculated a single common interaction term which assumes
 
that each relative treatment effect compared to a common
 
comparator treatment (i.e. paracentesis plus fluid replacement)
 
is impacted in the same way by the covariate in question, when
 
applicable (Dias  2012a). If the 95% Crl of the interaction term
 
did not overlap zero, we considered this statistically significant
 






If there were post­randomisation dropouts, we reanalysed the
 
results using the best­worst case scenario and worst­best case
 
scenario analyses as sensitivity analyses whenever possible. We
 
also performed a sensitivity analysis excluding the trials in which
 
mean or standard deviation, or both, were imputed, and we used
 






We followed the PRISMA­NMA statement while reporting (Hutton
 
2015). We presented the effect estimates with 95% CrI for each
 
pairwise comparison calculated from the direct comparisons and
 
network meta­analysis. We originally planned to present the
 
cumulative probability of the treatment ranks (i.e. the probability
 
that the intervention was within the top two, the probability
 
that the intervention was within the top three, etc) but we did
 
not present these because of the sparse data which can lead to
 
misinterpretation of results due to large uncertainty in the rankings
 
(the CrI was 0 to 1 for all the ranks) in graphs (SUCRA) (Salanti
 
2011). We plotted the probability that each intervention was best,
 
second best, third best, etc. for each of the different outcomes
 
(rankograms), which are generally considered more informative
 
(Salanti 2011; Dias 2012b), but we did not present these because of
 
the sparse data which can lead to misinterpretation of results due to
 
large uncertainty in the rankings (the CrI was 0 to 1 for all the ranks).
 
We uploaded all the raw data and the codes used for analysis in the
 
European Organization for Nuclear Research open source database
 




We presented 'Summary of findings' tables for all the primary
 
and secondary outcomes (see Primary outcomes;  Secondary
 
outcomes). We followed the approach suggested by Yepes­Nunez
 
and colleagues (Yepes­Nunez 2019). First, we calculated the direct
 
and indirect effect estimates (when possible) and 95% Crl using
 
the node­splitting approach (Dias  2010), that is, calculating the
 
direct estimate for each comparison by including only trials in
 
which there was direct comparison of interventions and the
 
indirect estimate for each comparison by excluding the trials
 
in which there was direct comparison of interventions (and
 
ensuring a connected network). Next, we rated the quality of direct
 
and indirect effect estimates using GRADE methodology which
 
takes into account the risk of bias, inconsistency (heterogeneity),
 
directness of evidence (including incoherence, the term used in
 
GRADE methodology for inconsistency in network meta­analysis),
 
imprecision, and publication bias (Guyatt 2011). We then presented
 
the relative and absolute estimates of the meta­analysis with the
 
best certainty of evidence (Yepes­Nunez 2019). We also presented
 
the 'Summary of findings' tables in a second format presenting all
 
the outcomes for selected interventions (Yepes­Nunez 2019): we
 
selected the four interventions (aldosterone antagonists plus loop
 
diuretics, paracentesis plus systemic vasoconstrictors, aldosterone
 
antagonists plus loop diuretics plus paracentesis plus fluid
 
replacement, and transjugular intrahepatic portosystemic shunt)
 
which were compared in the most trials (Table 1).
 
Recommendations for future research
 
We provided recommendations for future research in the
 
population, intervention, control, outcomes, period of follow­up,
 
and study design, based on the uncertainties that we identified
 






Results of the search
 
We identified 4877 references through electronic searches of
 
CENTRAL (n = 1095), MEDLINE Ovid (n = 2093), Embase Ovid (n =
 
875), Science Citation Index expanded (n = 779), ClinicalTrials.gov
 
(n = 35), and WHO Trials register (n = 0). After removing duplicate
 
references, there were 3890 references. We excluded 3713 clearly
 
irrelevant references through reading titles and abstracts. We
 
identified no additional references by reference searching and
 
by searching the EMA and FDA. We retrieved a total of 177­full
 
text references for further assessment in detail. We excluded 97
 
references (78 studies) for the reasons stated in the Characteristics
 
of excluded studies. There were six ongoing trials (seven references)
 
without interim data (Characteristics of ongoing studies).  Thus,
 
we included a total of 49 trials described in 73 references
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Figure 2. Study flow diagram.
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Chesta 1990; Ginès 1991; Strauss 1991; Acharya 1992; Bruno 1992;
 
Hagege 1992;  Ljubici  1994;  Sola  1994;  Ginès  1995;  Schaub  1995;
 




2002;  Sanyal 2003;  Salerno  2004;  Romanelli 2006;  Singh  2006a;
 
Singh 2006b; Lata 2007; Appenrodt 2008; Singh 2008; Licata 2009;
 
Narahara 2011; Raza 2011; Al Sebaey 2012; Amin 2012; Bari 2012;
 
Singh  2012a;  Singh  2013;  Ali  2014;  Hamdy  2014;  Tuttolomondo
 
2016;  Bureau 2017c;  Rai 2017;  Caraceni 2018;  Sola  2018). A total
 
of 3521 participants were randomised to different interventions.
 
The number of participants within each trial ranged from 20 to
 
440. A total of 2870 participants from 42 trials were included in
 




Acharya 1992; Hagege 1992;  Ljubici  1994;  Sola  1994; Ginès  1995;
 




2002;  Sanyal 2003;  Salerno  2004;  Romanelli 2006;  Singh  2006a;
 
Singh 2006b;  Lata 2007; Singh 2008;  Licata 2009; Narahara 2011;
 
Raza 2011;  Bari  2012;  Singh  2012a;  Singh  2013;  Ali  2014;  Hamdy
 
2014; Tuttolomondo 2016; Bureau 2017c; Rai 2017; Caraceni 2018;
 
Sola 2018). The mean or median age in the trials ranged from 43
 






1992;  Ljubici  1994;  Sola  1994;  Ginès  1995;  Lebrec 1996;  Chang
 
1997;  Fernandez­Esparrach 1997;  Graziotto 1997;  Mehta 1998;
 
Gentilini  1999a;  Rossle 2000;  Ginès  2002;  Moreau 2002;  Sanyal
 
2003;  Salerno  2004;  Romanelli 2006;  Singh  2006a;  Singh  2006b;
 
Lata 2007;  Appenrodt 2008;  Singh  2008;  Licata 2009;  Narahara
 




2017; Caraceni 2018; Sola 2018). The proportion of females ranged
 
from 0.0% to 47.6% in the trials that reported this information
 
(Gregory 1977; Fogel 1981; Descos 1983; Gines 1987; Salerno 1987;
 
Ginès 1991; Strauss 1991; Acharya 1992; Bruno 1992; Hagege 1992;
 
Ljubici  1994;  Sola  1994;  Ginès  1995;  Lebrec 1996;  Chang  1997;
 
Fernandez­Esparrach 1997;  Graziotto 1997; Mehta 1998;  Gentilini
 
1999a; Rossle 2000; Ginès 2002; Moreau 2002; Sanyal 2003; Salerno
 
2004;  Romanelli 2006;  Singh  2006a;  Singh  2006b;  Lata 2007;
 




2014; Tuttolomondo 2016; Bureau 2017c; Rai 2017; Caraceni 2018;
 
Sola 2018). The follow­up period in the trials ranged from 0.1 to 84
 
months in the trials that reported this information. Twenty­eight
 
trials had short­term follow­up (Gregory 1977; Fogel 1981; Descos
 




Esparrach 1997;  Mehta 1998;  Moreau 2002;  Singh  2006a;  Singh
 














two trials had long­term follow­up (Stanley 1989b; Romanelli 2006).
 
Twenty­five trials reported the proportion of participants who
 
had ascites grade 2: in 23 trials, none of the participants had
 
ascites grade 2; these trials included only participants with grade
 




Esparrach 1997; Graziotto 1997; Rossle 2000; Moreau 2002; Singh
 
2006a;  Singh  2006b;  Lata 2007;  Appenrodt 2008;  Singh  2008;  Al
 
Sebaey 2012;  Amin  2012;  Ali  2014;  Hamdy  2014;  Bureau 2017c);
 
in the remaining two trials, the proportion of participants who
 
had ascites grade 2 ranged from 65.0% to 83.1% (Romanelli
 
2006;  Caraceni 2018). Twenty trials reported the proportion of
 
participants who had refractory or recurrent ascites: in 19 trials,
 
all the participants had refractory or recurrent ascites (Ginès 1991;
 
Strauss 1991; Bruno 1992; Ginès  1995;  Lebrec 1996; Rossle 2000;
 




Tuttolomondo 2016;  Bureau 2017c;  Rai 2017); in the remaining
 
trial, the proportion of participants who had refractory or recurrent
 
ascites was 85.0% (Acharya 1992). Forty­one trials reported the
 
proportion of participants who had alcohol­related cirrhosis: in
 
two trials, none of the participants had alcohol­related cirrhosis
 
(Chang  1997;  Raza 2011); in four trials, all the participants had
 
alcohol­related cirrhosis (Gregory 1977;  Stanley 1989b;  Ljubici
 
1994;  Schaub  1995); in the remaining 35 trials, the proportion
 
of participants who had alcohol­related cirrhosis ranged from
 
2.0% to 90.6% (Gines  1987;  Salerno  1987;  Chesta 1990;  Ginès
 
1991;  Strauss 1991;  Acharya 1992;  Bruno  1992;  Hagege 1992;
 
Sola  1994;  Ginès  1995;  Lebrec 1996;  Fernandez­Esparrach 1997;
 
Mehta 1998;  Gentilini  1999a;  Rossle 2000;  Ginès  2002;  Moreau
 
2002;  Sanyal 2003;  Salerno  2004;  Romanelli 2006;  Singh  2006a;
 




2016;  Bureau 2017c;  Rai 2017;  Caraceni 2018;  Sola  2018).  Thirty­

three trials reported the proportion of participants who had viral­

related cirrhosis: in four trials, none of the participants had
 
viral­related cirrhosis (Gregory 1977; Stanley 1989b; Chesta 1990;
 
Ljubici  1994); in one trial, all the participants had viral­related
 
cirrhosis  (Chang 1997); in the remaining 28 trials, the proportion
 
of participants who had viral­related cirrhosis ranged from 5.6%
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2006;  Singh  2006a;  Singh  2006b;  Appenrodt 2008;  Singh  2008;
 
Licata 2009;  Narahara 2011;  Raza 2011;  Bari  2012;  Singh  2012a;
 
Singh 2013; Tuttolomondo 2016; Bureau 2017c; Rai 2017; Caraceni
 
2018;  Sola  2018). Twenty­two trials reported the proportion of
 
participants who had autoimmune disease­related cirrhosis: in 17
 
trials, none of the participants had autoimmune disease­related
 




Romanelli 2006; Singh 2006b; Appenrodt 2008; Licata 2009; Raza
 
2011; Singh 2013; Tuttolomondo 2016; Rai 2017); in the remaining
 
five trials, the proportion of participants who had autoimmune
 
disease­related cirrhosis ranged from 2.5% to 12.0% (Chesta 1990;
 
Singh 2006a; Singh 2008; Bari 2012; Singh 2012a). Only two trials
 
reported whether the participants received antibiotic prophylaxis
 
for spontaneous bacterial peritonitis (Ginès 2002; Caraceni 2018).
 
In one trial, all participants received antibiotic prophylaxis (Ginès
 
2002); in the other trial, 19.3% of participants received antibiotic
 
prophylaxis, but the reason for only a proportion of participants
 
receiving antibiotic prophylaxis was not stated (Caraceni 2018).
 
In 38 trials, patients with active other decompensation events
 
such as active gastrointestinal bleeding, hepatorenal syndrome, or
 








1997;  Graziotto 1997;  Mehta 1998;  Gentilini  1999a;  Ginès  2002;
 
Moreau 2002;  Sanyal 2003;  Salerno  2004;  Romanelli 2006;  Singh
 




2014;  Bureau 2017c;  Rai 2017;  Caraceni 2018;  Sola  2018).  In  the
 
remaining 11 trials, it was not clear whether patients with active
 
other decompensation events were included (Gregory 1977; Fogel
 
1981; Mchutchison 1989; Stanley 1989b; Schaub 1995; Rossle 2000;
 
Lata 2007; Appenrodt 2008; Licata 2009; Amin 2012; Tuttolomondo
 
2016). The interval between diagnosis and treatment was not
 
reported in any of the trials.
 
A total of 21 interventions were compared in these trials. Forty­

two trials (2870 participants) reported one or more outcomes for
 
this review (Gregory 1977;  Fogel 1981;  Descos 1983;  Gines  1987;
 
Salerno 1987; Chesta 1990; Ginès 1991; Strauss 1991; Acharya 1992;
 
Hagege 1992;  Ljubici  1994;  Sola  1994;  Ginès  1995;  Schaub  1995;
 






2007; Singh 2008; Licata 2009; Narahara 2011; Raza 2011; Bari 2012;
 
Singh  2012a;  Singh  2013;  Ali  2014;  Hamdy  2014;  Tuttolomondo
 
2016;  Bureau 2017c;  Rai 2017;  Caraceni 2018;  Sola  2018).  The
 
important characteristics, potential effect modifiers, and follow­up
 
in each trial is reported in Table 2. Overall, there does not seem to
 
be any systematic differences between the comparisons.
 
Funding: the source of funding for four trials was industries
 
who would benefit from the results of the study (Stanley
 
1989b;  Fernandez­Esparrach 1997;  Caraceni 2018;  Sola  2018);  24
 
trials received no additional funding or were funded by neutral
 
organisations with no vested interests in the results of the study
 






2008;  Licata 2009;  Bari  2012;  Singh  2012a;  Singh  2013;  Ali  2014;
 
Hamdy  2014;  Tuttolomondo 2016;  Bureau 2017c;  Rai 2017);  the
 
source of funding for the remaining 21 trials was unclear (Gregory
 
1977;  Fogel 1981;  Salerno  1987; Mchutchison 1989;  Chesta 1990;
 
Strauss 1991; Acharya 1992; Bruno 1992; Hagege 1992; Ljubici 1994;
 
Schaub 1995; Lebrec 1996; Graziotto 1997; Mehta 1998; Rossle 2000;
 










Risk of bias in included studies
 
The risk of bias is summarised in Figure 3, Figure 4, and in Table 3.
 
All the trials were at unclear or high risk of bias in at least one of the
 
domains and were considered to be at high risk of bias overall.
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Figure 3. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
 
across all included studies.
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Figure 4. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
 
Treatment for ascites in adults with decompensated liver cirrhosis: a network meta­analysis (Review)
 












                       










Treatment for ascites in adults with decompensated liver cirrhosis: a network meta­analysis (Review)
 








       
     
 
                       










Treatment for ascites in adults with decompensated liver cirrhosis: a network meta­analysis (Review)
 








       
               




           







               




             




         
   
                 
                   
           





       
 
                     
     
   
                   
           
         





       
   
















                 
         
                 
                   
           
           
 
                   
 
         
                     







         
   
               
                     
               
           
       
             
   
             
                 
               
               
                     
                     
                   
                 
                         
                   
                 
 
                       










With regards to sequence generation, twenty­two trials were at
 






Bari  2012;  Singh  2012a;  Singh  2013;  Ali  2014;  Bureau 2017c;  Rai
 
2017;  Caraceni 2018;  Sola  2018); the remaining 27 trials, which
 
did not provide sufficient information, were at unclear risk of bias
 
(Gregory 1977; Fogel 1981; Descos 1983; Salerno 1987; Mchutchison
 
1989;  Stanley 1989b;  Chesta 1990;  Acharya 1992;  Ginès  1995;
 




2002; Sanyal 2003; Salerno 2004; Lata 2007; Appenrodt 2008; Raza
 




With regards to allocation concealment, twenty­two trials were at
 
low risk of bias (Stanley 1989b; Strauss 1991; Bruno 1992; Hagege
 






Rai 2017; Caraceni 2018; Sola 2018); the remaining 27 trials, which
 
did not provide sufficient information, were at unclear risk of bias
 
(Gregory 1977; Fogel 1981; Descos 1983; Gines 1987; Salerno 1987;
 




Esparrach 1997; Mehta 1998; Gentilini 1999a; Rossle 2000; Moreau
 






With regards to the blinding of patients and healthcare providers,
 
five trials were at low risk of bias (Appenrodt 2008;  Raza 2011;
 
Bari  2012;  Ali  2014;  Sola  2018); 34 trials, which did not provide
 




1989b;  Chesta 1990;  Ginès  1991;  Strauss 1991;  Acharya 1992;
 
Bruno  1992;  Ljubici  1994;  Sola  1994;  Ginès  1995;  Schaub  1995;
 








2016; Bureau 2017c); the remaining 10 trials were at high risk of bias
 




With regards to blinding of outcome assessors, six trials were at
 
low risk of bias (Fernandez­Esparrach 1997; Appenrodt 2008; Raza
 
2011;  Bari  2012;  Ali  2014;  Sola  2018); 33 trials, which did not
 








Lebrec 1996; Chang 1997; Graziotto 1997; Gentilini  1999a; Rossle
 
2000; Ginès 2002; Moreau 2002; Sanyal 2003; Romanelli 2006; Lata
 












With regards to incomplete data, twenty­three trials were at low
 
risk  of  bias  (Gregory 1977;  Fogel 1981;  Salerno  1987;  Stanley
 






2009;  Narahara 2011;  Singh  2012a;  Singh  2013;  Tuttolomondo
 
2016;  Bureau 2017c;  Rai 2017); 25 trials were at unclear risk of
 
bias  (Descos 1983;  Gines  1987;  Mchutchison 1989;  Chesta 1990;
 
Ginès  1991;  Strauss 1991;  Acharya 1992;  Hagege 1992;  Ljubici
 
1994;  Sola  1994;  Ginès  1995;  Schaub  1995;  Lebrec 1996;  Chang
 
1997;  Mehta 1998;  Moreau 2002;  Singh  2006b;  Lata 2007;  Raza
 
2011;  Al Sebaey 2012;  Amin  2012;  Bari  2012;  Ali  2014;  Hamdy
 
2014; Caraceni 2018), because it was not clear whether there were
 
post­randomisation dropouts or whether the post­randomisation
 
dropouts were related to the outcomes (if there were post­

randomisation dropouts); the remaining trial was at high risk of bias
 
(Sola  2018), as the post­randomisation dropouts were probably
 








Singh 2013; Ali 2014; Sola 2018), as the important clinical outcomes
 
expected to be reported in such trials were reported; 40 trials were
 




1989;  Stanley 1989b;  Chesta 1990;  Ginès  1991;  Strauss 1991;
 




Graziotto 1997;  Mehta 1998;  Gentilini  1999a;  Rossle 2000;  Ginès
 
2002;  Moreau 2002;  Sanyal 2003;  Salerno  2004;  Romanelli 2006;
 




2016;  Bureau 2017c;  Rai 2017), as a protocol published prior to
 
recruitment was not available; the remaining trial was at high risk of
 
selective outcome reporting bias (Caraceni 2018), as adverse events
 
were clearly collected, but not reported adequately.
 
Other potential sources of bias
 








The network plots (where relevant) are available in Figure 1. The
 
inconsistency factor plots (where relevant) are available in Figure
 
5. The differences in the fixed­effect versus random­effects model,
 
where relevant, are available in Figure 6. The model fit is available
 
in Table 4. The effect estimates are available in Table 5. A formal
 
subgroup analysis was not possible for grade of ascites because the
 
trials that provided this information included only grade 3 ascites
 
or included a mixture of grade 2 and grade 3 ascites, i.e. there were
 
no trials that included grade 2 ascites only. However, there was
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Figure 5. Inconsistency factor plots showing the inconsistency factors for the outcomes with direct and indirect
 
evidence available for one or more comparisons. There was no evidence of inconsistency except for hospital stay. A
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TIPS = Transjugular intrahepatic portosystemic shunt
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Figure 6. Forest plots showing the outcomes for which the random­effects model were different from the fixed­

effect model. The more conservative random­effects model was used. In this figure, mortality at maximal follow­

up, any adverse events (number of people), and resolution of ascites are shown. Figure 7 shows the remaining
 
outcomes (other decompensation events and length of hospital stay), the other outcomes in which the fixed­
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Figure 7. Forest plots showing the outcomes for which the random­effects model were different from the fixed­

effect model. The more conservative random­effects model was used. In this figure, other decompensation events
 
and length of hospital stay are shown. Figure 6 shows the remaining outcomes (mortality at maximal follow­

up, any adverse events (number of people), and resolution of ascites), the other outcomes in which the fixed­
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The 95% credible intervals of the probability ranks were wide and
 
included 0 and 1 in most comparisons for all the primary and
 
secondary outcomes. This was probably because of the sparse
 
data from small trials. Therefore, we did not present the ranking
 
probabilities (in a table), rankograms, and SUCRA plots as we
 
considered that presenting this information would be unhelpful
 
and potentially misleading and would ignore the differences in
 
systematic errors in the trials.
 
The certainty of evidence was low or very low for all the
 
comparisons. This was because most of the trials included in
 
the comparison were at unclear or high risk of bias for at least
 
one risk of bias domain at the outcome level (downgraded one
 
level) and the sample size was small (downgraded one level).
 
This resulted in low­certainty evidence. In comparisons where
 
the wide credible intervals overlapped significant clinical effect
 
and no effect, we downgraded one more level for imprecision
 
(downgraded one level). There was also evidence of heterogeneity
 
(called inconsistency in the GRADE system; not to be confused
 
with inconsistency in direct and indirect estimates in the context
 
of network meta­analysis) for resolution of ascites and other
 
decompensation events (downgraded one level)
 
Mortality at maximal follow­up
 
Thirty­four trials (2548 participants) reported mortality at maximal
 
follow­up (Gregory 1977;  Fogel 1981;  Descos 1983;  Gines  1987;
 




Gentilini 1999a; Rossle 2000; Ginès 2002; Moreau 2002; Sanyal 2003;
 
Salerno  2004;  Romanelli 2006;  Singh  2006a;  Singh  2006b;  Singh
 
2008;  Licata 2009;  Narahara 2011;  Bari  2012;  Singh  2012a;  Singh
 
2013; Ali 2014; Bureau 2017c; Rai 2017; Caraceni 2018; Sola 2018). A
 
total of 18 treatments were compared in these trials. Two trials were
 
not connected to the network because they were the only trials for
 
the comparisons and had zero events in one of the intervention
 
groups (Acharya 1992; Ali 2014), and thus were excluded from the
 
analysis. The network had 16 connected treatments (32 trials; 2448
 
participants). There was no evidence of inconsistency according to
 
model fit, inconsistency factor, and the 'between­design' variance
 
0.16 (95% CrI 0.00 to 10.02). The random­effects model was used
 
because it was more conservative, even though the model fit was
 
similar to the fixed­effect model. The 'between­study variance' was
 
0.02 (95% CrI 0.00 to 0.27).
 
There was no evidence of differences between interventions in any
 
of the direct comparisons or in the comparisons included in the
 
network meta­analysis (i.e. there was no statistically significant
 
difference in any of the comparisons) (Table 5) (very low­certainty
 
evidence; Summary of findings 2). The sensitivity analysis indicated
 
that the different scenarios (best­best and worst­worst scenarios)
 
for imputing missing data showed different interpretation of
 
results; therefore, the results have to be interpreted with caution.
 
There was also no evidence of differences between the
 
comparisons not included in the network meta­analysis.

•	 Aldosterone antagonists plus paracentesis plus fluid
 
replacement (0/20; 0%) versus aldosterone antagonists plus
 




•	 Systemic vasoconstrictors (1/30; 3.3%) versus no active
 






Fourteen trials (761 participants) reported serious adverse events
 
(with respect to number of people) (Acharya 1992; Hagege 1992;
 




2017; Sola 2018). A total of 14 treatments were compared in these
 
trials. Ten trials were not connected to the network because they
 




2012a; Singh 2013; Ali 2014; Rai 2017); two trials were not connected
 
to the network because they were the only trials for the comparison
 
and had zero events in one of the intervention groups (Ljubici
 
1994; Lata 2007); the remaining trials had no common treatments,
 
and therefore were not connected (Acharya 1992; Sola 2018). Only
 
two treatments were compared in each of the remaining trials
 
(Acharya 1992;  Sola  2018). Therefore, random­effects, network
 




There was no evidence of differences in any of the direct
 
comparisons for which it was possible to calculate the effect
 




•	 Aldosterone antagonists plus paracentesis plus fluid
 
replacement versus aldosterone antagonists plus loop diuretics:
 




•	 Aldosterone antagonists plus loop diuretics plus systemic
 
vasodilator versus aldosterone antagonists plus loop diuretics
 
plus systemic vasoconstrictors plus systemic vasodilator: OR
 




•	 Aldosterone antagonists plus loop diuretics plus paracentesis
 
plus fluid replacement (0/10; 0%) versus aldosterone
 
antagonists plus loop diuretics (1/11; 9.1%) (1 trial; 21
 
participants; very low­certainty evidence);
 
•	 Paracentesis plus systemic vasoconstrictors (0/84; 0%) versus
 
paracentesis plus fluid replacement (1/85; 1.2%) (4 trials; 169
 
participants; very low­certainty evidence).
 
There was no change in the results by using the best­worst and
 
worst­best scenarios for imputing missing data.
 
Two trials (111 participants) reported serious adverse events (with
 
respect to number of events) (Salerno  1987; Ginès  2002). A total
 
of three treatments were compared in these trials. One trial was
 
not connected to the network because it was the only trial for the
 
comparison and had zero events in one of the intervention groups
 
(Ginès 2002). Only two treatments were compared in the remaining
 
trial  (Salerno  1987; 41 participants). Therefore, random­effects,
 
network meta­analysis, checking for inconsistency, or subgroup
 
analyses were not applicable.
 
There was no evidence of differences in the only direct comparison
 
for which it was possible to calculate the effect estimates (i.e. there
 
was no statistically significant difference): aldosterone antagonists
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plus loop diuretics versus paracentesis plus fluid replacement:
 
rate ratio: 1.30 (95% CrI 0.27 to 7.16; 1 trial; 41 participants;
 
very low­certainty evidence; Summary of findings 2).  In  the
 
remaining comparison, transjugular intrahepatic portosystemic
 
shunt versus paracentesis plus fluid replacement, there were
 
10 serious advents in 35 participants receiving transjugular
 
intrahepatic portosystemic shunt (28.6 serious adverse events per
 
100 participants) compared to no serious adverse events in 35
 
participants receiving paracentesis plus fluid replacement (1 trial;
 
70 participants; very low­certainty evidence).
 
Health­related quality of life
 
One trial (431 participants) reported health­related quality of
 
life (EQ­5D) (Caraceni 2018). For EQ­5D, a higher score indicates
 
better health­related quality of life. A total of two treatments
 
were compared in this trial. Since only one trial reported
 
the outcome, random­effects, network meta­analysis, checking
 
for inconsistency, or subgroup analyses were not applicable.
 
Aldosterone antagonists plus loop diuretics plus albumin had
 
better health­related quality of life than aldosterone antagonists
 
plus loop diuretics plus paracentesis plus fluid replacement: MD
 
0.06 (95% CrI 0.03 to 0.09; 1 trial; 431 participants; low­certainty
 
evidence). The standard deviation was reported in the trial:
 
therefore, sensitivity analysis of excluding trials in which standard
 




Eight trials (462 participants) reported any adverse events (with
 
respect to number of people) (Chesta 1990;  Hagege 1992;  Singh
 
2006a;  Singh  2006b;  Singh  2008;  Narahara 2011;  Bari  2012;
 
Sola  2018). A total of six treatments were compared in these
 
trials. Two trials were not connected to the network because
 
they were the only trials for the comparisons and had zero
 
events in one of the intervention groups (Narahara 2011)  or
 
had unconnected treatments (Sola 2018). The network had three
 
connected treatments (6 trials; 229 participants). There were no
 
triangular or quadrangular loops; therefore, inconsistency was not
 
checked. The random­effects model was used because it was more
 
conservative, even though the model fit was similar to the fixed­





There was no evidence of differences in any of the direct
 
comparisons or network meta­analysis (i.e. there was no
 
statistically significant difference in any of the comparisons
 
included in the network meta­analysis) (Table 5) (very low­certainty
 
evidence; Summary of findings 2). There was no change in the
 




The results of the remaining two comparisons which could not be
 
included in the network meta­analysis are as follows.

•	 10 participants among 30 participants (10/30; 33.3%) receiving
 
transjugular intrahepatic portosystemic shunt compared to no
 
participant of 30 participants (0/30; 05) receiving paracentesis
 
plus fluid replacement developed 'any adverse events' (1 trial;
 
60 participants; very low­certainty evidence).
 
•	 There was no evidence of differences between systemic
 
vasoconstrictors plus albumin versus no active intervention OR
 




Five trials (314 participants) reported any adverse events (number
 
of events) (Chesta 1990;  Bari  2012;  Singh  2013;  Rai 2017;  Sola
 
2018). A total of 10 treatments were compared in these trials. Two
 
trials were not connected to the network because of unconnected
 
treatments (Rai 2017; Sola 2018). The network had six connected
 
treatments (3 trials; 116 participants). There was no evidence of
 
inconsistency according to model fit and the 'between­design'
 
variance 0.17 (95% CrI 0.00 to 3.49). The inconsistency factor plot
 
could not be obtained since there was only one trial for the closed
 
loops and heterogeneity could not be calculated. The fixed­effect
 




The following direct comparisons were statistically significant (both
 




•	 Aldosterone antagonists plus loop diuretics plus systemic
 
vasoconstrictors plus paracentesis plus fluid replacement
 
versus aldosterone antagonists plus loop diuretics plus
 
paracentesis plus fluid replacement: rate ratio 0.07 (95% CrI 0.00
 
to 0.47; 1 trial; 25 participants; low­certainty evidence);
 
•	 Systemic vasoconstrictors plus albumin versus no active
 




There was no evidence of differences between the treatments
 
in the remaining direct comparisons (i.e. the remaining direct
 
comparisons were not statistically significant) or in the network
 
meta­analysis (Table 5) (very low­certainty evidence; Summary of
 
findings  2). The sensitivity analysis indicated that the different
 
scenarios (best­worst and worst­best scenarios) for imputing
 
missing data showed different interpretation of results; therefore,
 
the results have to be interpreted with caution.
 
Liver transplantation at maximal follow­up
 
Nineteen trials (1568 participants) reported liver transplantation
 
at maximal follow­up (Fogel 1981;  Hagege 1992;  Graziotto 1997;
 






2018; Sola 2018). A total of 14 treatments were compared in these
 
trials. Five trials were not connected to the network because they
 
had zero events in both intervention groups (Fogel 1981; Hagege
 
1992;  Singh  2012a;  Singh  2013;  Rai 2017); three trials were not
 
connected to the network because of unconnected treatments
 
(Romanelli 2006; Caraceni 2018; Sola 2018). The network had four
 
connected treatments (11 trials; 596 participants). There were no
 
triangular or quadrangular loops; therefore, inconsistency was
 
not checked. The fixed­effect model was used because it had
 
equivalent results and model fit to the random­effects model.
 
There was no evidence of differences in any of the direct
 
comparisons or network meta­analysis (i.e. there was no
 
statistically significant difference in any of the comparisons) (Table
 
5) (very low­certainty evidence; Summary of findings 2). There was
 
no change in the results by using the best­worst and worst­best
 
scenarios for imputing missing data.
 
The effect estimates in the comparisons with unconnected
 
treatments were as follows.
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•	 Aldosterone antagonists plus loop diuretics plus albumin versus
 
aldosterone antagonists plus loop diuretics: HR 0.22 (95%
 




•	 Aldosterone antagonists plus loop diuretics plus albumin versus
 
aldosterone antagonists plus loop diuretics plus paracentesis
 
plus fluid replacement: HR 1.03 (95% CrI 0.54 to 2.00; 1 trial; 431
 
participants; very low­certainty evidence);
 
•	 Systemic vasoconstrictors plus albumin versus no active
 
intervention: HR 1.44 (95% CrI 0.96 to 2.15; 1 trial; 173
 
participants; very low­certainty evidence).
 
The number of people who underwent liver transplantation in the
 
trials with zero events are as follows.
 
•	 Aldosterone antagonists plus loop diuretics (0/27; 0%) versus
 
paracentesis plus fluid replacement (0/26; 0%) (1 trial; 53
 
participants; very low­certainty evidence);
 
•	 Aldosterone antagonists plus loop diuretics (0/61; 0%) versus
 




•	 Aldosterone antagonists plus loop diuretics plus systemic
 
vasoconstrictors (0/35; 0%) versus aldosterone antagonists plus
 




•	 Aldosterone antagonists plus loop diuretics plus systemic
 
vasoconstrictors plus systemic vasodilator (0/15; 0%) versus
 
aldosterone antagonists plus loop diuretics (0/15; 0%) (1 trial; 30
 
participants; very low­certainty evidence);
 
•	 Aldosterone antagonists plus loop diuretics plus systemic
 
vasodilator (0/15; 0%) versus aldosterone antagonists plus loop
 




•	 Aldosterone antagonists plus loop diuretics plus systemic
 
vasoconstrictors plus paracentesis plus fluid replacement (0/13;
 
0%) versus aldosterone antagonists plus loop diuretics plus
 
paracentesis plus fluid replacement (0/12; 0%) (1 trial; 25
 
participants; very low­certainty evidence);
 
•	 Aldosterone antagonists plus loop diuretics plus systemic
 
vasoconstrictors plus systemic vasodilator (0/15; 0%) versus
 
aldosterone antagonists plus loop diuretics plus systemic
 




•	 Aldosterone antagonists plus loop diuretics plus systemic
 
vasodilator (0/15; 0%) versus aldosterone antagonists plus loop
 
diuretics plus systemic vasoconstrictors (0/15; 0%) (1 trial; 30
 
participants; very low­certainty evidence);
 
•	 Aldosterone antagonists plus loop diuretics plus systemic
 
vasoconstrictors plus systemic vasodilator (0/15; 0%) versus
 
aldosterone antagonists plus loop diuretics plus systemic
 




Resolution of ascites at maximal follow­up
 
None of the trials reported symptomatic resolution of ascites (for
 
example, resolution of shortness of breath) at maximal follow­

up. Twenty trials (1217 participants) reported resolution of ascites
 
(by ultrasound) at maximal follow­up (Gregory 1977; Descos 1983;
 
Salerno  1987;  Chesta 1990;  Strauss 1991;  Hagege 1992;  Lebrec
 
1996; Fernandez­Esparrach 1997; Graziotto 1997; Gentilini  1999a;
 




2017). A total of 14 treatments were compared in these trials. Two
 
trials were not connected to the network because they were the
 
only trials for the comparison and had zero events in one of the
 
intervention groups (Graziotto 1997;  Rai 2017) and another trial
 
was not connected because of unconnected treatments. One more
 
trial had four arms with zero events in all four arms (Singh 2013).
 
One comparison could be included in the network meta­analysis
 
as there were some events in the remaining trials of the same
 
comparison, but the other comparisons could not be included
 
(Singh  2013). The network had nine connected treatments (17
 
trials; 1007 participants). There were no triangular or quadrangular
 
loops; therefore, inconsistency was not checked. The random­

effects model was used because it was more conservative and had
 








•	 Transjugular intrahepatic portosystemic shunt versus
 
paracentesis plus fluid replacement: HR 8.37 (95% CrI 1.97 to
 
62.68; 6 trials; 392 participants; very low­certainty evidence);
 
•	 Aldosterone antagonists plus paracentesis plus fluid
 
replacement versus paracentesis plus fluid replacement alone:
 




•	 No active treatment versus aldosterone antagonists plus loop
 
diuretics: HR 0.15 (95% CrI 0.04 to 0.43 ; 1 trial; 43 participants;
 
low­certainty evidence) (i.e. aldosterone antagonists plus loop
 




•	 Loop diuretics versus aldosterone antagonists plus loop
 
diuretics plus paracentesis plus fluid replacement: HR 1.90 (95%
 
CrI 1.03 to 3.76 ; 1 trial; 84 participants; low­certainty evidence).
 
There was no evidence of differences between the treatments
 
in the remaining direct comparisons (i.e. the remaining direct
 
comparisons were not statistically significant) (Table 5) (very low­

certainty evidence). In the network meta­analysis, the following
 
comparisons were statistically significant:

•	 Transjugular intrahepatic portosystemic shunt versus
 
paracentesis plus fluid replacement: HR 9.44 (95% CrI 1.93 to
 




There was no evidence of differences between the treatments in
 
the remaining comparisons in the network meta­analysis (Table 5)
 
(very low­certainty evidence; Summary of findings 2). There was
 
no change in the results by using the best­worst and worst­best
 
scenarios for imputing missing data.
 
The effect estimates in the comparisons with unconnected
 
treatments were as follows.
 
•	 Aldosterone antagonists versus paracentesis plus reinfusion: HR
 




The number of people who had resolution of ascites in the trials
 
with zero events are as follows.
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•	 Paracentesis plus reinfusion (2/12; 16.7%) versus paracentesis
 




•	 Aldosterone antagonists plus loop diuretics plus systemic
 
vasoconstrictors plus systemic vasodilator (0/15; 0%) versus
 
aldosterone antagonists plus loop diuretics (0/15; 0%) (1 trial; 30
 
participants; very low­certainty evidence)
 
•	 Aldosterone antagonists plus loop diuretics plus systemic
 
vasodilator (0/15; 0%) versus aldosterone antagonists plus loop
 




•	 Aldosterone antagonists plus loop diuretics plus systemic
 
vasoconstrictors plus paracentesis plus fluid replacement (5/13;
 
38.5%) versus aldosterone antagonists plus loop diuretics plus
 
paracentesis plus fluid replacement (0/12; 0%) (1 trial; 25
 
participants; very low­certainty evidence)
 
•	 Aldosterone antagonists plus loop diuretics plus systemic
 
vasoconstrictors plus systemic vasodilator (0/15; 0%) versus
 
aldosterone antagonists plus loop diuretics plus systemic
 




•	 Aldosterone antagonists plus loop diuretics plus systemic
 
vasodilator (0/15; 0%) versus aldosterone antagonists plus loop
 
diuretics plus systemic vasoconstrictors (0/15; 0%) (1 trial; 30
 
participants; very low­certainty evidence)
 
•	 Aldosterone antagonists plus loop diuretics plus systemic
 
vasoconstrictors plus systemic vasodilator (0/15; 0%) versus
 
aldosterone antagonists plus loop diuretics plus systemic
 




Other features of decompensation at maximal follow­up
 
Twenty­seven trials (1821 participants) reported other features of
 








Romanelli 2006; Lata 2007; Singh 2008; Licata 2009; Narahara 2011;
 
Bari 2012; Singh 2013; Bureau 2017c; Rai 2017; Sola 2018). A total
 
of 15 treatments were compared in these trials. Two trials were
 
not connected to the network because they were the only trials for
 
the comparisons and had zero events in one of the intervention
 
groups (Acharya 1992; Rai 2017). The network had 13 connected
 
treatments (25 trials; 1756 participants). There was no evidence of
 
inconsistency according to the inconsistency factor plot or model
 
fit. We could not obtain convergence for the design­by­treatment
 
analysis. The random­effects model was used because it was more
 
conservative and had a large between­study variance of 6.25 (95%
 




The following direct comparisons were in favour of:

•	 Aldosterone antagonists plus loop diuretics versus paracentesis
 
plus fluid replacement: rate ratio 2.04 (95% CrI 1.39 to
 
3.08; 4 trials; 242 participants; very low­certainty evidence)
 
(i.e. paracentesis plus fluid replacement versus aldosterone
 




•	 Aldosterone antagonists plus loop diuretics plus paracentesis
 
plus fluid replacement versus aldosterone antagonists plus loop
 




•	 Aldosterone antagonists plus paracentesis plus fluid
 
replacement versus aldosterone antagonists plus loop diuretics
 
plus systemic vasoconstrictors: 7/12 (0.6 other decompensation
 
events per participant) versus 0/13 (no decompensation events
 
per participant) (1 trial; 15 participants).
 
There was no evidence of differences between the treatments
 
in the remaining direct comparisons (i.e. the remaining direct
 
comparisons were not statistically significant) (Table 5) (very low­

certainty). In the network meta­analysis, the following comparisons
 
were in favour of:
 
•	 Aldosterone antagonists plus loop diuretics versus paracentesis
 
plus fluid replacement: rate ratio 2.04 (95% CrI 1.37 to 3.10)
 
(i.e. paracentesis plus fluid replacement versus aldosterone
 




•	 Aldosterone antagonists plus loop diuretics plus paracentesis
 
plus fluid replacement versus aldosterone antagonists plus loop
 
diuretics: rate ratio 0.51 (95% CrI 0.32 to 0.80)
 
•	 Transjugular intrahepatic portosystemic shunt versus
 
aldosterone antagonists plus loop diuretics: rate ratio 0.57 (95%
 
CrI 0.35 to 0.92)
 
•	 Loop diuretics versus aldosterone antagonists plus loop
 
diuretics: rate ratio 0.47 (95% CrI 0.22 to 0.96)
 
•	 Aldosterone antagonists plus loop diuretics plus
 
peritoneovenous shunt versus aldosterone antagonists plus
 
loop diuretics: rate ratio 0.41 (95% CrI 0.23 to 0.73)
 
•	 Systemic vasoconstrictors plus albumin versus aldosterone
 
antagonists plus loop diuretics plus peritoneovenous shunt: rate
 
ratio 4.65 (95% CrI 1.06 to 20.84) i..e. aldosterone antagonists
 
plus loop diuretics plus peritoneovenous shunt versus systemic
 




There was no evidence of differences between the treatments in
 
the remaining comparisons in the network meta­analysis (Table 5)
 
(very low­certainty evidence; Summary of findings 2).
 




•	 Aldosterone antagonists plus paracentesis plus fluid
 
replacement (0/20; 0 events) versus aldosterone antagonists
 
plus loop diuretics (3/20; 15 events per 100 participants) (1 trial;
 
40 participants; very low­certainty evidence)
 
•	 Aldosterone antagonists plus loop diuretics plus systemic
 
vasoconstrictors plus paracentesis plus fluid replacement (0/13;
 
0 events) versus aldosterone antagonists plus loop diuretics
 
plus paracentesis plus fluid replacement (7/12; 58.3 events per
 




Length of hospital stay (days)
 
Fifteen trials (1086 participants) reported length of hospital stay
 
(days) (all admissions until maximal follow­up) (Fogel 1981;
 
Descos 1983;  Gines  1987;  Chesta 1990;  Ginès  1991;  Hagege
 
1992;  Ginès  1995;  Schaub  1995;  Gentilini  1999a;  Rossle 2000;
 
Moreau 2002;  Salerno  2004;  Licata 2009;  Tuttolomondo 2016;
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Bureau 2017c). A total of 10 treatments were compared in these
 
trials. One trial was not connected to the network because
 
it had treatments unconnected to network (Descos 1983).  The
 
network had eight connected treatments. There was evidence of
 
inconsistency according to the 'between­design' variance 11.04
 
(95% CrI 0.05 to 24.30) and inconsistency factor, but not by model
 
fit; therefore, there is uncertainty in the validity of NMA results:
 
direct comparisons are more reliable. The random­effects model
 
was used because it had better model fit. The 'between­study
 
variance' was 20.10 (95% CrI 8.86 to 24.79).
 
The following direct comparisons were in favour of:

•	 Aldosterone antagonists plus loop diuretics versus paracentesis
 
plus fluid replacement: MD 14.00 days (95% CrI 9.19 to 18.52; 4
 
trials; 218 participants; low­certainty evidence), i.e. paracentesis
 
plus fluid replacement versus aldosterone antagonists plus loop
 




•	 Aldosterone antagonists plus loop diuretics plus albumin versus
 
aldosterone antagonists plus loop diuretics: MD ­9.28 days
 




There was no evidence of differences between the treatments
 
in the remaining direct comparisons (i.e. the remaining direct
 
comparisons were not statistically significant) (Table 5).  In  the
 




•	 Aldosterone antagonists plus loop diuretics versus paracentesis
 
plus fluid replacement: MD 11.81 days (95% CrI 6.92 to 16.67;
 
low­certainty evidence), i.e. paracentesis plus fluid replacement
 
versus aldosterone antagonists plus loop diuretics versus
 
paracentesis (MD ­11.81 days (95% CrI ­16.67 to ­6.92)
 
•	 Paracentesis plus systemic vasoconstrictors versus aldosterone
 
antagonists plus loop diuretics: MD ­11.60 days (95% CrI ­21.67
 
to ­1.68; low­certainty evidence)
 
•	 Transjugular intrahepatic portosystemic shunt versus
 
aldosterone antagonists plus loop diuretics: MD ­17.25 days
 
(95% CrI ­28.47 to ­6.17; low­certainty evidence).
 
There was no evidence of differences between the treatments in
 
the remaining comparisons in the network meta­analysis (Table
 
5). There was no imputation of mean or standard deviation in the
 
trials. Therefore, sensitivity analysis excluding trials in which mean
 








Four trials (150 participants) reported treatment costs (Mehta
 
1998;  Singh  2006a;  Singh  2008;  Hamdy  2014).  We  used  an
 
international exchange rate based on purchasing power parities
 
(PPP) to convert cost estimates to USA dollars (USD), and we
 
used the gross domestic product (GDP) deflators (or implicit
 
price deflators for GDP) to convert cost estimates to 2018 USD
 
using PPP conversion rates and GDP deflator values available
 
from the International Monetary Fund in the World Economic
 




A total of three treatments were compared in the four trials. All the
 
trials were connected to the network (after imputation of standard
 
deviation for one trial). There were no triangular or quadrangular
 
loops; therefore, inconsistency was not checked. The random­

effects model was used because of the model fit and because
 
the random­effects model was the more conservative model.
 
The 'between­study variance' was 2,458,624 (95% CrI 265,431 to
 
64,689,849). Given the extremely high between­study variance, we
 




Treatment costs for paracentesis plus systemic vasoconstrictors
 
was lower than that for paracentesis plus fluid replacement in all
 
the three trials that reported this information (Table 6). For the
 
other comparison, paracentesis plus reinfusion versus paracentesis
 
plus fluid replacement, the standard deviation was not reported;
 
therefore, it was not clear whether there were differences in
 




Data were sufficient to perform only the following subgroup
 
analysis: duration of follow­up (short­term, medium­term, and
 
long­term). There were no subgroup differences for any of the
 
outcomes where there were at least two different subgroups
 
represented in the analyses.
 
There were insufficient data for the remaining subgroup analyses
 
or only one subgroup was represented in the analyses. Although a
 
formal test for subgroup differences was not relevant for grade of
 
ascites, as the trials included either only ascites 3 or a mixture of
 
ascites 2 and ascites 3 (or did not provide information on the grade
 
of ascites), we have presented the subgroup estimates of grade 3
 
ascites only in Table 7, when possible. Similarly, we have presented
 
the results for recurrent and refractory ascites only in Table 8, when
 
possible. Some comparisons became statistically nonsignificant, as
 
could be expected when fewer than 50% trials were included for
 
the analysis, but there were no major differences that would have
 




All sensitivity analyses were presented under the outcome.
 
Assessment of reporting biases
 
Since there was no meaningful way in which to rank these studies
 
(i.e. there was no specific change in the risk of bias in the studies,
 
sample size, or the control group used over time), we were
 
unable to perform the comparison­adjusted funnel plot. However,
 
important outcomes such as all­cause mortality and adverse events
 






Summary of main results
 
We performed a systematic review and network meta­analysis of all
 
the treatments available for ascites in people with decompensated
 
liver cirrhosis. A total of 49 trials, including a total of 3521
 
participants, were included in this review. A total of 21 interventions
 
were compared in these trials. A total of 42 trials including 2870
 
participants were included for one or more outcomes of this review
 
(Gregory 1977; Fogel 1981; Descos 1983; Gines 1987; Salerno 1987;
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Chesta 1990; Ginès 1991; Strauss 1991; Acharya 1992; Hagege 1992;
 
Ljubici  1994;  Sola  1994;  Ginès  1995;  Schaub  1995;  Lebrec 1996;
 
Fernandez­Esparrach 1997;  Graziotto 1997; Mehta 1998;  Gentilini
 




2008;  Licata 2009;  Narahara 2011;  Raza 2011;  Bari  2012;  Singh
 
2012a;  Singh  2013;  Ali  2014;  Hamdy  2014;  Tuttolomondo 2016;
 
Bureau 2017c; Rai 2017; Caraceni 2018; Sola 2018).
 
Overall, 36.8% of the trial participants who received the standard
 
treatment of paracentesis plus fluid replacement died during the
 
follow­up period ranging from one week to 11 months. There
 
was no evidence of differences in mortality or serious adverse
 
events in any of the direct comparisons or network meta­analysis.
 
However, the credible intervals were wide, and clinically important
 




The health­related quality of life was reported in only one
 
trial comparing aldosterone antagonists plus loop diuretics plus
 
albumin versus aldosterone antagonists plus loop diuretics plus
 
paracentesis plus fluid replacement. The mean difference was 0.06.
 
The minimum clinically important difference for EQ­5D in people
 
with cirrhosis is not known. In other conditions, a difference of
 
0.04 to 0.20 is clinically important (Asher 2018; Sims 2018; Hoehle
 
2019; Kato 2019). Therefore, it is not clear whether the difference of
 
0.06 with aldosterone antagonists plus loop diuretics plus albumin
 
and aldosterone antagonists plus loop diuretics plus paracentesis
 
plus fluid replacement is clinically important. It should also be
 
pointed out that there is no information on whether this difference
 
was reproducible, as this was the only trial for this comparison.
 




There were differences between the different groups in 'any'
 
adverse events, but none of the comparisons in which there were
 
differences could be considered as 'standard of care'; therefore
 
the implications of these findings are not clinically relevant. The
 
resolution of ascites was greater with transjugular intrahepatic
 
portosystemic shunt versus paracentesis plus fluid replacement.
 
While the resolution of ascites was greater by adding aldosterone
 
antagonists to paracentesis plus fluid replacement, this was based
 
on a single small trial of high risk of bias (sample size: 36
 




The number of other decompensation events and the length
 
of hospital stay were more with aldosterone antagonists plus
 
loop diuretics versus paracentesis plus fluid replacement. In the
 
network meta­analysis, a number of other treatments including
 
transjugular intrahepatic portosystemic shunt had fewer other
 
decompensation events and shorter length of hospital stay than
 
aldosterone antagonists plus loop diuretics without paracentesis.
 
Therefore, aldosterone antagonists plus loop diuretics without
 
paracentesis seems to be the worst among the common treatments
 
compared in this review.
 
Treatment costs with paracentesis plus systemic vasoconstrictors
 
was lower than that for paracentesis plus fluid replacement
 
in all three trials that reported this information, although
 
the between study variance was extremely high and meta­

analysis was not performed. Furthermore, in the presence of
 
considerable uncertainty in benefits and harms of different
 
treatments, treatment costs alone cannot determine whether one
 
intervention is better than another.
 
The weighted median mortality in the paracentesis plus fluid
 
replacement group was 36.8% in 11 months. The sample size
 
required to detect a relative risk reduction of 20% in the
 
experimental group, with type I error of 5%, and type II error of 20%,
 
is 1282 participants. Although approximately 20% of people with
 
liver cirrhosis develop ascites, the majority may be grade 2 and may
 
be amenable to treatment with diuretics. However, a significant
 
proportion may be grade 3, refractory, or recurrent. There is paucity
 
of information on the incidence or prevalence of grade 3 refractory
 
or recurrent ascites. One small study in Tunisia estimated that
 
about 20% of all hospital admissions in people with cirrhosis was
 
due to refractory ascites (Ennaifer 2014). If even 5% of hospital
 
admissions due to liver cirrhosis relate to grade 3 refractory or
 




There were approximately 44 other decompensation events per
 
100 participants in the paracentesis plus fluid replacement group.
 
In addition to causing death, decompensation usually results in
 
hospital admissions and significant costs to the health service.
 
Therefore, 'any decompensation event' is another possible primary
 
outcome. Assuming that the variance was equal to the mean in an
 
ordinary Poisson distribution commonly used to analyse recurrent
 
events (that happen independently, although this is a questionable
 
assumption), for a 20% relative risk reduction in the experimental
 
group, with type I error of 5%, and type II error of 20%, the sample
 




In terms of the interventions to be compared in future
 
trials, paracentesis plus fluid replacement was the commonest
 
intervention in this review. So, it should be considered as one of
 
the interventions in future trials. Aldosterone antagonists plus loop
 
diuretics instead of paracentesis plus fluid replacement appears to
 
increase the other decompensation events and length of hospital
 
stay (and paracentesis or TIPS may be required in people who
 
do not respond to diuretics), although this is based on trials
 
at high risk of bias. However, adding diuretics to paracentesis
 
plus fluid replacement is one of the options for intervention
 
(particularly, because this is currently the recommended treatment
 
by AASLD and EASL, although there is no evidence to consider this
 
superior to paracentesis plus fluid replacement alone); transjugular
 
intrahepatic portosystemic shunt may be another option. Such
 
shunts may be effective in preventing variceal rebleeding (Qi 2016),
 
but they may increase hepatic encephalopathy (Saab 2006; Zhou
 
2019). Therefore, the impact of decompensation events on quality
 
of life and ability to perform daily activities, social activities, and
 
work should be evaluated as part of future trials.
 
Overall completeness and applicability of evidence
 
There did not seem to be any restrictions based on the etiology or
 
the presence of other features of decompensation in the trials that
 
provided this information. Therefore, the results of the study are
 
applicable in people with cirrhosis resulting from varied aetiologies
 
having ascites. However, it appears that the trials included mainly
 
people with grade 3, refractory, or recurrent ascites. Therefore,
 
the findings of this review are applicable only to such people.
 
There is currently no information on which diuretic is better for
 
people with cirrhosis and grade 2 ascites which is not refractory
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or recurrent. Therefore, feasible randomised clinical trials which
 
look at the potential effects of different diuretics are necessary.
 
The incidence of grade 3, recurrent, or refractory ascites may be a
 
suitable outcome for such a trial.
 
Furthermore, 38 trials excluded participants with active other
 
decompensation features such as active variceal bleeding,
 
hepatorenal syndrome, and grade III or grade IV hepatic
 
encephalopathy, while the remaining 11 trials did not report
 
whether they included any participants with active other
 
decompensation features. Therefore, the results of the review are
 
only applicable to people without active other decompensation
 
events. Accordingly, more evidence on ascites treatment seems
 




Quality of the evidence
 
The overall certainty (quality) of evidence was very low. One
 
of the main reasons for the very low certainty of evidence was
 
the unclear or high risk of bias in all the trials. It is possible
 
to perform trials at low risk of bias in certain comparisons:
 
randomisation can be performed using standard methods, for
 
example, web­based central randomisation; an intention­to­treat
 
analysis can be performed; and a protocol should be published
 
prior to recruitment. However, blinding of healthcare providers
 
and participants may not be possible if TIPS is used as one of
 
the interventions. It is possible to achieve blinding with careful
 
planning for other comparisons, for example by using placebos for
 
diuretics if the trial was about adding diuretics to paracentesis plus
 




Another major reason for the very low certainty of evidence was
 
imprecision: the trials had small sample sizes and the credible
 
intervals overlapped clinically significant benefits and clinically
 
significant harms for most comparisons. Therefore, future trials
 




We used clinical outcomes; therefore, there is no issue of
 
indirectness due to outcomes. There was no suggestion that
 
the potential effect modifiers were systematically different across
 
comparisons (i.e. there was no concern about the transitivity
 
assumption). While there was evidence of inconsistency according
 
to the model fit, inconsistency in factor plots, and between­design
 
variance, an analysis of a subset of participants with grade 3
 
ascites (when possible) did not result in major differences in the
 
interpretation of findings. Similarly, an analysis of a subset of
 
participants with refractory or recurrent ascites (when possible)
 
did not result in major differences in the interpretation of findings.
 
However, one cannot rule out inconsistency ('incoherence'
 
according to GRADE terminology).
 
There was no meaningful way to rank these studies (i.e. there
 
was no specific change in the risk of bias in the studies, sample
 
size, or the control group used over time); we have completed a
 
thorough search for studies on effectiveness. However, different
 
sets of trials were included for different outcomes: only 30% to
 
70% of the trials reported mortality, serious adverse events, liver
 
transplantation, resolution of ascites, and other decompensation
 
events, even though these outcomes would have been routinely
 




Potential biases in the review process
 
We selected a range of databases to search without using any
 
language restrictions and conducted the network meta­analysis
 
according to NICE DSU guidance. In addition, we have analysed
 
using the fixed­effects model and random­effects model and
 
assessed and reported inconsistency whenever possible. These are
 
the strengths of the review process.
 
We have excluded studies that compared variations in duration
 
or dose in the different interventions. Hence, this review does
 
not provide information on whether one variation is better than
 
another. Another major limitation of this review was the paucity
 
of data: the trials were small. This paucity of data decreases the
 
confidence in the results.
 
All of the network meta­analyses included only sparse data from
 
trials, most of which were at high risk of bias. However, the potential
 
effect modifiers in the trials that reported them were broadly
 
similar across comparisons. The results of direct comparisons and
 
indirect comparisons were similar for the most outcomes where
 
we could assess this. Therefore, the concern about the transitivity
 
assumption was low. However, this cannot be ruled out.
 
We included only randomised clinical trials, which were known
 
to focus mostly on benefits and did not collect and report
 
harms in a detailed manner. A significant effort was required to
 
identify nonrandomised studies that reported on harm. It was
 
also challenging to assess the risk of bias in those studies. If
 
future randomised clinical trials are powered on mortality or other
 
decompensation events, a systematic review on adverse events
 
from observational studies will likely be unnecessary.
 




This is the first network meta­analysis on the topic. There have been
 
several systematic reviews and direct comparisons of different
 
interventions for treating people with cirrhosis and ascites.
 
Guo and colleagues assessed the role of midodrine in people with
 
cirrhosis and ascites (Guo  2016). They did not find any benefits
 
of midodrine in terms of clinical outcomes despite improving
 
surrogate outcomes such as response rates and plasma renin
 
activity (Guo  2016). They also found that midodrine could be
 
potentially harmful when used as a substitute for fluid replacement
 
after paracentesis (Guo  2016). We did not find any evidence of
 
benefit or harms of systemic vasoconstrictors in people with ascites
 
and cirrhosis. This may be because of the different methods used
 
for meta­analysis: we have considered that the co­interventions
 
such as the diuretics or vasodilators used could influence the effect
 
of systemic vasoconstrictors and treated these as different 'nodes'
 
in the network meta­analysis, while Guo and colleagues combined
 
the trials despite differences in diuretics or vasodilators used.
 
The method used for meta­analysis (Bayesian versus frequentist
 
method) could be an additional reason for the difference.
 
Simonetti and colleagues assessed the role of different fluids
 
after paracentesis and found no evidence of difference in
 
outcomes between different fluids used after paracentesis
 
including reinfusion of ascitic fluid (Simonetti 2019). While we are
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unable to comment on different fluids after paracentesis since
 
we did not explore this, we agree that there was no evidence of
 




Saab and colleagues found that TIPS was more effective in the
 
resolution of ascites than paracentesis and fluid replacement,
 
but found that the incidence of hepatic encephalopathy was
 
increased (Saab  2006). However, they did not find evidence of
 
differences in other decompensation events. Our network meta­

analysis also demonstrated that TIPS may be more effective in the
 
resolution of ascites than paracentesis plus fluid replacement. We
 
did not analyse the individual decompensation events separately.
 
Therefore, we are unable to comment on whether hepatic
 








Based on very low­certainty evidence, there is considerable
 
uncertainty about whether other interventions decrease mortality,
 
adverse events, or liver transplantation compared to paracentesis
 
plus fluid replacement in people with decompensated liver
 
cirrhosis and ascites. Based on very low­certainty evidence,
 
transjugular intrahepatic portosystemic shunt and adding
 
aldosterone antagonists to paracentesis plus fluid replacement
 
may increase the resolution of ascites compared to paracentesis
 
plus fluid replacement. Based on very low­certainty evidence,
 
aldosterone antagonists plus loop diuretics may increase the
 






Further well­designed randomised clinical trials are necessary.
 




Study design: parallel, randomised clinical trial
 




Interventions/control: transjugular intrahepatic portosystemic
 
shunt versus diuretics plus paracentesis plus fluid replacement
 








Secondary outcomes: health­related quality of life,
 
decompensation events, adverse events, resolution of ascites, and
 








For a simple two­arm parallel randomised clinical trial, the sample
 
size required to detect or reject a relative risk reduction of 20% in
 
the experimental group from the control group proportion of 36.8%
 






Trials need to be conducted and reported according to the SPIRIT
 
(Standard Protocol Items: Recommendations for Interventional
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Post­randomisation dropouts: not stated
 
Revised sample size: 40
 




Ascites grade 2: 0 (0.0%)
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Autoimmune disease­related cirrhosis: not stated
 
Other causes for cirrhosis: 10 (25.0%)
 










Interventions Group 1: Aldosterone antagonists plus paracentesis plus fluid replacement (n = 20) 
Further details: Spironolactone 100 mg/day after resolution of ascites + large volume paracentesis 5 
litres daily and supported by dextran (30% to 50% of ascitic fluid removed) 
Group 2: Aldosterone antagonists plus loop diuretics (n = 20) 
Further details: Spironolactone 200 mg/day + furosemide 40 mg/day doubled after third day for 15 
days (route not stated) 
Outcomes Outcomes reported: mortality at maximal follow­up, serious adverse events (number of people), other 
features of decompensation at maximal follow­up 
Follow­up (months): 0.5 
Notes Source of funding: not stated 
Trial name/trial registry number: not stated 
Attempts were made to contact the authors in November 2018. 
Risk of bias 
Bias Authors' judgement Support for judgement 
Random sequence genera­ Unclear risk Comment: this information was not available. 
tion (selection bias) 
Allocation concealment Unclear risk Comment: this information was not available. 
(selection bias) 




Blinding of outcome as­ Unclear risk Comment: this information was not available. 
sessment (detection bias) 
All outcomes 
Incomplete outcome data Unclear risk Comment: this information was not available. 
(attrition bias) 
All outcomes 
Selective reporting (re­ Unclear risk Comment: pre­published protocol was not available. 
porting bias) 
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Al Sebaey 2012  (Continued) 
Participants Country: Egypt 
Period of recruitment: not stated 
Number randomised: 125 
Post­randomisation dropouts: not stated 
Revised sample size: 125 
Average age (years): 50 
Females: 56 (44.8%) 
Ascites grade 2: 0 (0.0%) 
Ascites grade 3: 125 (100.0%) 
Refractory or recurrent ascites: not stated 
Alcohol­related cirrhosis: not stated 
Viral­related cirrhosis: not stated 
Autoimmune disease­related cirrhosis: not stated 
Other causes for cirrhosis: not stated 





Interventions Group 1: Paracentesis plus systemic vasoconstrictors (n = 50) 
Further details: Large volume paracentesis (details not available) + terlipressin 1 mg at onset of LVP, 8 
hours, and 16 hours or midodrine 5 to 10 mg orally TDS for 3 days) 
Group 2: Paracentesis plus fluid replacement (n = 75) 
Further details: Large volume paracentesis (no further details) + HES or low dose albumin or high dose 
albumin 
Outcomes None of the outcomes of interest were reported. 
Notes Source of funding: not stated 
Trial name/trial registry number: not stated 
Attempts were made to contact the authors in November 2018. 
Risk of bias 
Bias Authors' judgement Support for judgement 
Random sequence genera­
tion (selection bias) 
Unclear risk Comment: this information was not available. 
Allocation concealment 
(selection bias) 













Unclear risk Comment: this information was not available. 
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Al Sebaey 2012  (Continued) 
Selective reporting (re­
porting bias) 
Unclear risk Comment: pre­published protocol was not available. 











Post­randomisation dropouts: 6 (9.1%)
 
Revised sample size: 60
 
Reasons for post­randomisation dropouts: lost to follow­up
 




Ascites grade 2: 0 (0.0%)
 
Ascites grade 3: 60 (100.0%)
 
Refractory or recurrent ascites: not stated
 
Alcohol­related cirrhosis: not stated
 
Viral­related cirrhosis: not stated
 
Autoimmune disease­related cirrhosis: not stated
 
Other causes for cirrhosis: not stated
 












5. Hepatocellular carcinoma (HCC)
 
6. Portal vein thrombosis
 
Interventions	 Group 1: Systemic vasoconstrictors (n = 30)
 
Further details: Midodrine (dose not clear, but probably 2.5 mg TDS) for 2 weeks
 








Notes	 Source of funding (quote): "No funding (author replies)"
 
Trial name/trial registry number: not stated
 




Bias	 Authors' judgement Support for judgement
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Unclear risk Comment: there was an equal number of dropouts in the two groups as they 
were lost­to­follow­up, but not clear if these were related to outcomes. 
Selective reporting (re­
porting bias) 
Low risk Comment: a pre­published protocol was not available, but the important out­
comes were reported or obtained by email. 











Post­randomisation dropouts: not stated
 
Revised sample size: 60
 




Ascites grade 2: 0 (0.0%)
 
Ascites grade 3: 60 (100.0%)
 
Refractory or recurrent ascites: not stated
 
Alcohol­related cirrhosis: not stated
 
Viral­related cirrhosis: not stated
 
Autoimmune disease­related cirrhosis: not stated
 
Other causes for cirrhosis: not stated
 
Prophylactic antibiotics for subacute bacterial peritonitis: not stated
 
Interventions	 Group 1: Systemic vasoconstrictors (n = 30)
 
Further details: Midodrine 2.5 mg TDS for 2 weeks
 




Outcomes	 None of the outcomes of interest were reported.
 
Notes	 Source of funding: not stated
 
Trial name/trial registry number: not stated
 




Bias	 Authors' judgement Support for judgement
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Unclear risk Comment: this information was not available. 
Selective reporting (re­
porting bias) 
Unclear risk Comment: pre­published protocol was not available. 











Post­randomisation dropouts: 0 (0.0%)
 
Revised sample size: 24
 




Ascites grade 2: 0 (0.0%)
 
Ascites grade 3: 24 (100.0%)
 








Other causes for cirrhosis: 2 (8.3%)
 












drine 12.5 mg post­paracentesis TDS for 2 days
 




min (8 g/L of removed ascites) was infused immediately after the end of paracentesis
 
Outcomes	 None of the outcomes of interest were reported.
 
Notes Source of funding (quote): "Authors’ declaration of personal and funding interests: The authors do not
 
have anything to declare".
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Library Better health. Cochrane Database of Systematic Reviews
 
Appenrodt 2008  (Continued) 
Trial name/trial registry number: not stated 
Attempts were made to contact the authors in November 2018. 
Risk of bias 
Bias Authors' judgement Support for judgement 
Random sequence genera­ Unclear risk Comment: this information was not available. 
tion (selection bias) 
Allocation concealment Unclear risk Comment: this information was not available. 
(selection bias) 
Blinding of participants Low risk Quote: "Neither the patient nor the physician was aware of the treatment 
and personnel (perfor­ arm". 
mance bias)  Comment: placebo was used to achieve this. 
All outcomes 
Blinding of outcome as­ Low risk Quote: "Neither the patient nor the physician was aware of the treatment 
sessment (detection bias)  arm". 
All outcomes Comment: placebo was used to achieve this. 
Incomplete outcome data Low risk Comment: there were no post­randomisation dropouts. 
(attrition bias) 
All outcomes 
Selective reporting (re­ Unclear risk Comment: pre­published protocol was not available. 
porting bias) 











Post­randomisation dropouts: 2 (7.4%)
 
Revised sample size: 25
 








Ascites grade 2: not stated
 










Other causes for cirrhosis: 2 (8.0%)
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Bari 2012  (Continued) 
Interventions Group 1: Paracentesis plus systemic vasoconstrictors (n = 12) 
Further details: Large volume paracentesis (details not available) + midodrine 10 mg oral TDS + long­
acting octreotide 20 mg/month for 6 months 
Group 2: Paracentesis plus fluid replacement (n = 13) 
Further details: Large volume paracentesis (details not available) + albumin 8 g/L of ascites removed 
once 
Outcomes Outcomes reported: mortality at maximal follow­up, any adverse events (number of people), any ad­
verse events (number of events), liver transplantation at maximal follow­up, other features of decom­
pensation at maximal follow­up 
Follow­up (months): 10 
Notes Source of funding (quote): "Supported by a VA merit review grant and National Institutes of Health 
grants K­24 DK02727 and P­30DK 034989" 
Trial name/trial registry number: NCT00108355 
Attempts were made to contact the authors in November 2018. 
Risk of bias 
Bias Authors' judgement Support for judgement 
Random sequence genera­ Low risk Quote: "The random treatment allocation codes were generated at an inde­
tion (selection bias) pendent biostatistical center by the study statistician using SAS version 8.2 
(SAS Institute Inc, Cary, NC)". 
Allocation concealment Low risk Quote: "A list with allocation codes was sent to the pharmacy that assigned the 
(selection bias) participants to interventions based on allocation codes". 




Blinding of outcome as­ Low risk Quote: "double­blind, placebo­controlled trial" 
sessment (detection bias) 
All outcomes 
Incomplete outcome data Unclear risk Comment: there were 2 post­randomisation dropouts because of SBP, but the 
(attrition bias)  diagnosis would have been made only after the intervention was administered 
All outcomes and may or may not be related to the intervention. 
Selective reporting (re­ Unclear risk Comment: pre­published protocol was not available. 
porting bias) 











Post­randomisation dropouts: 0 (0.0%)
 
Revised sample size: 35
 
Average age (years): 54
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Ascites grade 2: 0 (0.0%)
 








Autoimmune disease­related cirrhosis: not stated
 
Other causes for cirrhosis: not stated
 








Interventions Group 1: Paracentesis plus reinfusion (n = 17) 
Further details: Large volume paracentesis + polyamide fibre haemofilter (FH 88, Gambro) 
Group 2: Paracentesis plus fluid replacement (n = 18) 
Further details: Large volume paracentesis + albumin 4 to 6 g/litre of ascites removed 
Outcomes None of the outcomes of interest were reported. 
Notes Source of funding: not stated 
Trial name/trial registry number: not stated 
Attempts were made to contact the authors in November 2018. 
Risk of bias 
Bias Authors' judgement Support for judgement 
Random sequence genera­ Low risk Quote: "patients were randomly assigned by the sealed envelope method on 
tion (selection bias) the basis of a computer generated list". 
Allocation concealment Low risk Quote: "patients were randomly assigned by the sealed envelope method on 
(selection bias) the basis of a computer generated list". 




Blinding of outcome as­ Unclear risk Comment: this information was not available. 
sessment (detection bias) 
All outcomes 
Incomplete outcome data Low risk Comment: there were no post­randomisation dropouts. 
(attrition bias) 
All outcomes 
Selective reporting (re­ Unclear risk Comment: pre­published protocol was not available. 
porting bias) 
Other bias Low risk Comment: no other bias noted 
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Post­randomisation dropouts: 0 (0.0%)
 
Revised sample size: 62
 




Ascites grade 2: 0 (0.0%)
 








Autoimmune disease­related cirrhosis: not stated
 
Other causes for cirrhosis: not stated
 












Interventions	 Group 1: Transjugular intrahepatic portosystemic shunt (n = 29)
 




Group 2: Paracentesis plus fluid replacement (n = 33)
 
Further details: Large volume paracentesis + albumin 4 to 6 g/litre of ascites removed
 
Outcomes	 Outcomes reported: mortality at maximal follow­up, liver transplantation at maximal follow­up, resolu­

tion of ascites at maximal follow­up (by ultrasound), other features of decompensation at maximal fol­





Notes	 Source of funding (quote): "This work was funded by the French Ministry of Health, by a grant from the
 




Trial name/trial registry number: NCT00222014
 




Bias	 Authors' judgement Support for judgement
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Low risk Comment: there were no post­randomisation dropouts. 
Selective reporting (re­
porting bias) 
Unclear risk Comment: pre­published protocol was not available. 











Post­randomisation dropouts: 9 (2.0%)
 
Revised sample size: 431
 
Reasons for post­randomisation dropouts: withdrew consent, wrong inclusion
 




Ascites grade 2: 358 (83.1%)
 
Ascites grade 3: 73 (16.9%)
 






Autoimmune disease­related cirrhosis: not stated
 
Other causes for cirrhosis: 56 (13.0%)
 














6. Albumin use for the treatment of ascites in the month preceding enrolment
 
Interventions	 Group 1: Aldosterone antagonists plus loop diuretics + albumin (n = 218)
 
Further details: antialdosteronic drug (no further details) ≥ 200 mg/day + furosemide ≥25 mg/day + hu­

man albumin 20% 40 gm twice weekly for 2 weeks and then weekly for 18 months
 
Group 2: Aldosterone antagonists plus loop diuretics + paracentesis plus fluid replacement (n = 213)
 




Outcomes	 Outcomes reported: mortality at maximal follow­up, liver transplantation at maximal follow­up, quality
 




Notes	 Source of funding (quote): "The trial was funded by the competitive peer­reviewed grant FARM6P824B
 
from the Italian Medicine Agency".
 
Trial name/trial registry number: 2008–000625–19 and NCT01288794
 
Attempts were made to contact the authors in November 2018.
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Bias Authors' judgement Support for judgement 
Random sequence genera­
tion (selection bias) 
Low risk Quote: "computer­generated" 
Allocation concealment 
(selection bias) 















Unclear risk Comment: there were post­randomisation dropouts, but it was not clear 
whether they were related to the intervention or the outcome. 
Selective reporting (re­
porting bias) 
High risk Comment: outcomes such as adverse events were collected but not reported 
adequately. 











Post­randomisation dropouts: not stated
 
Revised sample size: 26
 




Ascites grade 2: 0 (0.0%)
 
Ascites grade 3: 26 (100.0%)
 








Other causes for cirrhosis: 0 (0.0%)
 








Interventions	 Group 1: Aldosterone antagonists plus loop diuretics (n = 13)
 
Further details: Spironolactone 100 to 400 mg/day and furosemide 80 to 240 mg/day oral for 4 to 9 days
 
Group 2: Paracentesis plus fluid replacement (n = 13)
 
Treatment for ascites in adults with decompensated liver cirrhosis: a network meta­analysis (Review)
 








       
                         
             
                               
       
         
                 
   
                     
         
         
         
                     
         









       
       
         
         
             
   
                       






Library Better health. Cochrane Database of Systematic Reviews
 
Chang 1997  (Continued) 
Further details: Large volume paracentesis + albumin 6 to 8 g/litre of ascites removed 
Outcomes None of the outcomes of interest were reported. 
Notes Source of funding (quote): "This work was supported by a grant from the National Science Council of 
the Republic of China (NSC842331­B075­005)". 
Trial name/trial registry number: not stated 
Attempts were made to contact the authors in November 2018. 
Risk of bias 
Bias Authors' judgement Support for judgement 
Random sequence genera­ Low risk Quote: "Patients were then randomly allocated to two groups (random num­
tion (selection bias) ber table)". 
Allocation concealment Unclear risk Comment: this information was not available. 
(selection bias) 




Blinding of outcome as­ Unclear risk Comment: this information was not available. 
sessment (detection bias) 
All outcomes 
Incomplete outcome data Unclear risk Comment: two patients were excluded from the analysis it was not clear 
(attrition bias)  whether this was pre­randomisation or post­randomisation. 
All outcomes 
Selective reporting (re­ Unclear risk Comment: pre­published protocol was not available. 
porting bias) 











Post­randomisation dropouts: not stated
 
Revised sample size: 31
 




Ascites grade 2: 0 (0.0%)
 
Ascites grade 3: 31 (100.0%)
 








Other causes for cirrhosis: 6 (19.4%)
 
Prophylactic antibiotics for subacute bacterial peritonitis: not stated
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Chesta 1990  (Continued) 
Exclusion criteria 
1. Other features of decompensation 
Interventions Group 1: Aldosterone antagonists plus loop diuretics (n = 14) 
Further details: Spironolactone 100 mg/day and if no response within a week, furosemide 40 to 80 mg/ 
day + spironolactone 200 mg oral ­ duration not stated (until hospital discharge) 
Group 2: Paracentesis plus fluid replacement (n = 17) 
Further details: Large volume paracentesis + albumin 4 to 6 g/litre of ascites removed (initial patients 
over 4 to 5 days; later patients in a single session) 
Outcomes Outcomes reported: any adverse events (number of people), any adverse events (number of events), 
resolution of ascites at maximal follow­up (by ultrasound), other features of decompensation at maxi­
mal follow­up, length of hospital stay (days) (all admissions until maximal follow­up) 
Follow­up (months): 18 
Notes Source of funding: not stated 
Trial name/trial registry number: not stated 
Attempts were made to contact the authors in November 2018. 
Risk of bias 
Bias Authors' judgement Support for judgement 
Random sequence genera­ Unclear risk Comment: this information was not available. 
tion (selection bias) 
Allocation concealment Unclear risk Comment: this information was not available. 
(selection bias) 




Blinding of outcome as­ Unclear risk Comment: this information was not available. 
sessment (detection bias) 
All outcomes 
Incomplete outcome data Unclear risk Comment: this information was not available. 
(attrition bias) 
All outcomes 
Selective reporting (re­ Unclear risk Comment: pre­published protocol was not available. 
porting bias) 











Post­randomisation dropouts: not stated
 
Revised sample size: 131
 
Average age (years): 57
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Ascites grade 2: 0 (0.0%)
 
Ascites grade 3: 131 (100.0%)
 
Refractory or recurrent ascites: not stated
 
Alcohol­related cirrhosis: not stated
 
Viral­related cirrhosis: not stated
 
Autoimmune disease­related cirrhosis: not stated
 
Other causes for cirrhosis: not stated
 






Interventions Group 1: Aldosterone antagonists (n = 72) 
Further details: Spironolactone 100 mg to 200 mg/day for 4 weeks 
Group 2: Paracentesis plus reinfusion (n = 59) 
Further details: Large volume paracentesis with reinfusion or concentrated ascites or unconcentrated 
ascites 
Outcomes Outcomes reported: mortality at maximal follow­up, resolution of ascites at maximal follow­up (by ul­
trasound), length of hospital stay (days) (all admissions until maximal follow­up) 
Follow­up (months): 1.2 
Notes Source of funding: not stated 
Trial name/trial registry number: ENTAC 
Attempts were made to contact the authors in November 2018. 
Risk of bias 
Bias Authors' judgement Support for judgement 
Random sequence genera­ Unclear risk Comment: this information was not available. 
tion (selection bias) 
Allocation concealment Unclear risk Comment: this information was not available. 
(selection bias) 




Blinding of outcome as­ Unclear risk Comment: this information was not available. 
sessment (detection bias) 
All outcomes 
Incomplete outcome data Unclear risk Comment: this information was not available. 
(attrition bias) 
All outcomes 
Selective reporting (re­ Unclear risk Comment: pre­published protocol was not available. 
porting bias) 
Other bias Low risk Comment: no other bias noted 
Treatment for ascites in adults with decompensated liver cirrhosis: a network meta­analysis (Review)
 








       
 




       
       
         
     
       
         
             
                     
                                 
         
               
                             
                 
                       
         
                 
   
         
         
                     
     
                       
 
                       
     
           
   
                       


















Post­randomisation dropouts: 0 (0.0%)
 
Revised sample size: 36
 




Ascites grade 2: 0 (0.0%)
 
Ascites grade 3: 36 (100.0%)
 




Viral­related cirrhosis: not stated
 
Autoimmune disease­related cirrhosis: not stated
 
Other causes for cirrhosis: not stated
 








Interventions	 Group 1: Aldosterone antagonists plus paracentesis plus fluid replacement (n = 19)
 
Further details: Spironolactone 75 mg TDS for 4 weeks + total paracentesis with IV albumin infusion (8 g
 
per litre of ascitic fluid removed)
 
Group 2: Paracentesis plus fluid replacement (n = 17)
 
Further details: total paracentesis with IV albumin infusion (8 g per litre of ascitic fluid removed)
 




Notes	 Source of funding (quote): "This study was supported by a grant from SEARLE."
 
Trial name/trial registry number: not stated
 




Bias	 Authors' judgement Support for judgement
 








Blinding of participants Unclear risk Quote: "Physicians participating in the study did not know the treatment as­

and personnel (perfor­ signed to each patient".
 




Blinding of outcome as­ Low risk Quote: "Physicians participating in the study did not know the treatment as­
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Fernandez­Esparrach 1997  (Continued) 
Selective reporting (re­ Unclear risk 
porting bias) 
Comment: pre­published protocol was not available. 











Post­randomisation dropouts: 0 (0.0%)
 
Revised sample size: 90
 




Ascites grade 2: not stated
 
Ascites grade 3: not stated
 
Refractory or recurrent ascites: not stated
 
Alcohol­related cirrhosis: not stated
 
Viral­related cirrhosis: not stated
 
Autoimmune disease­related cirrhosis: not stated
 
Other causes for cirrhosis: 6 (6.7%)
 
Prophylactic antibiotics for subacute bacterial peritonitis: not stated
 
Interventions	 Group 1: Loop diuretics (n = 29)
 
Further details: Furosemide 40 mg to 400 mg/day for 6 weeks orally
 
Group 2: Aldosterone antagonists plus loop diuretics (n = 61)
 
Further details: Sequential or combination of spironolactone 100 mg/day + furosemide 40 mg to 120
 
mg/day oral for 6 weeks
 
Outcomes	 Outcomes reported: mortality at maximal follow­up, liver transplantation at maximal follow­up, other
 










Trial name/trial registry number: not stated
 




Bias	 Authors' judgement Support for judgement
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Low risk Comment: there were no post­randomisation dropouts. 
Selective reporting (re­
porting bias) 
Unclear risk Comment: pre­published protocol was not available. 











Post­randomisation dropouts: 0 (0.0%)
 
Revised sample size: 126
 




Ascites grade 2: not stated
 
Ascites grade 3: not stated
 








Other causes for cirrhosis: not stated
 










Interventions	 Group 1: Aldosterone antagonists plus loop diuretics + albumin (n = 63)
 
Further details: Albumin 12.5 mg/day IV weekly + potassium canreonate 200 mg to 400 mg/day and
 
furosemide 40 mg to 160 mg/day for 3 years
 
Group 2: Aldosterone antagonists plus loop diuretics (n = 63)
 




Outcomes	 Outcomes reported: mortality at maximal follow­up, resolution of ascites at maximal follow­up (by ul­











Virali e Cirrosi Epatica), Rome, and the Italian Liver Foundation, Florence, Italy"
 
Trial name/trial registry number: not stated
 
Attempts were made to contact the authors in November 2018.
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Bias Authors' judgement Support for judgement 
Random sequence genera­
tion (selection bias) 
Unclear risk Comment: this information was not available. 
Allocation concealment 
(selection bias) 













Low risk Comment: there were no post­randomisation dropouts. 
Selective reporting (re­
porting bias) 
Unclear risk Comment: pre­published protocol was not available. 











Post­randomisation dropouts: not stated
 
Revised sample size: 117
 




Ascites grade 2: 0 (0.0%)
 
Ascites grade 3: 117 (100.0%)
 






Autoimmune disease­related cirrhosis: not stated
 
Other causes for cirrhosis: 27 (23.1%)
 








Interventions	 Group 1: Aldosterone antagonists plus loop diuretics (n = 59)
 




Group 2: Paracentesis plus fluid replacement (n = 58)
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Gines 1987  (Continued) 
Further details: Repeated paracentesis removing 4 to 6 litres per day + 40 g albumin after each paracen­
tesis 
Outcomes Outcomes reported: mortality at maximal follow­up, other features of decompensation at maximal fol­
low­up, length of hospital stay (days) (all admissions until maximal follow­up) 
Follow­up (months): 11 
Notes Source of funding (quote): "This work was supported by grants from Comision Asesora de investigacion 
Cientffico y Tecnica (CAICYT 2643­83 and 2114­81) and from Fondo de Investigaciones Sanitarias do la 
Seguridad Social (FISS, 82­410)". 
Trial name/trial registry number: not stated 
Attempts were made to contact the authors in November 2018. 
Risk of bias 
Bias Authors' judgement Support for judgement 
Random sequence genera­ Low risk Quote: "Patients were then randomly allocated (random number table)". 
tion (selection bias) 
Allocation concealment Unclear risk Comment: this information was not available. 
(selection bias) 




Blinding of outcome as­ Unclear risk Comment: this information was not available. 
sessment (detection bias) 
All outcomes 
Incomplete outcome data Unclear risk Comment: this information was not available. 
(attrition bias) 
All outcomes 
Selective reporting (re­ Unclear risk Comment: pre­published protocol was not available. 
porting bias) 











Post­randomisation dropouts: not stated
 
Revised sample size: 89
 




Ascites grade 2: not stated
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Other causes for cirrhosis: 19 (21.3%) 
Prophylactic antibiotics for subacute bacterial peritonitis: not stated 
Exclusion criteria 
1. Other features of decompensation 
Interventions Group 1: Aldosterone antagonists plus loop diuretics + peritoneovenous shunt (n = 48) 
Further details: Le Veen shunt + spironolactone 200 mg/day + furosemide 80 mg/day 
Group 2: Aldosterone antagonists plus loop diuretics + paracentesis plus fluid replacement (n = 41) 
Further details: Repeated paracentesis removing 4 to 6 litres per day + 200 mL of 20% albumin for each 
paracentesis + spironolactone 200 mg/day + furosemide 80 mg/day 
Outcomes Outcomes reported: mortality at maximal follow­up, other features of decompensation at maximal fol­
low­up, length of hospital stay (days) (all admissions until maximal follow­up) 
Follow­up (months): 14 
Notes Source of funding (quote): "Supported by a grant (2018/84) from the Fondo de Investigaciones Sani­
tarias de la Seguridad Social and by the Fundació Catalana per a l'Estudi de les Malalties del Fetge" 
Trial name/trial registry number: not stated 
Attempts were made to contact the authors in November 2018. 
Risk of bias 
Bias Authors' judgement Support for judgement 
Random sequence genera­ Low risk Quote: "The patients from each hospital were then randomly assigned to two 
tion (selection bias) groups with use of a random­number table". 
Comment: this information was not available. 
Allocation concealment Unclear risk Comment: this information was not available. 
(selection bias) 




Blinding of outcome as­ Unclear risk Comment: this information was not available. 
sessment (detection bias) 
All outcomes 
Incomplete outcome data Unclear risk Comment: this information was not available. 
(attrition bias) 
All outcomes 
Selective reporting (re­ Unclear risk Comment: pre­published protocol was not available. 
porting bias) 
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Post­randomisation dropouts: not stated
 
Revised sample size: 81
 




Ascites grade 2: not stated
 










Other causes for cirrhosis: 8 (9.9%)
 






Interventions	 Group 1: Aldosterone antagonists plus loop diuretics + peritoneovenous shunt (n = 39)
 
Further details: Le Veen shunt + spironolactone 200 mg/day + furosemide 80 mg/day
 
Group 2: Aldosterone antagonists plus loop diuretics + paracentesis plus fluid replacement (n = 42)
 
Further details: Repeated paracentesis removing 4 to 6 litres per day + 200 mL of 20% albumin for each
 
paracentesis + spironolactone 200 mg/day + furosemide 80 mg/day
 
Outcomes	 Outcomes reported: mortality at maximal follow­up, other features of decompensation at maximal fol­





Notes	 Source of funding (quote): "Supported by grants from Fondo de Investigaciones Sanitarias de la Se­

guridad Social (FISS 93/0610) and Direccion General de Investigacion Cientifica y Tecnica (DGICYT PM
 
91­0216). A. Gin,s and J. Sal5 were granted by FISS (91/5549 and 93/0610, respectively)".
 
Trial name/trial registry number: not stated
 




Bias	 Authors' judgement Support for judgement
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Post­randomisation dropouts: 0 (0.0%)
 
Revised sample size: 70
 




Ascites grade 2: not stated
 






Viral­related cirrhosis: not stated
 
Autoimmune disease­related cirrhosis: not stated
 
Other causes for cirrhosis: not stated
 










Interventions	 Group 1: Transjugular intrahepatic portosystemic shunt (n = 35)
 
Further details: Transjugular intrahepatic portosystemic shunt, dilated to 8 mm to 10 mm
 
Group 2: Paracentesis plus fluid replacement (n = 35)
 
Further details: total paracentesis + albumin 8 g/litre of ascites removed
 
Outcomes	 Outcomes reported: mortality at maximal follow­up, serious adverse events (number of events), liver
 






Notes	 Source of funding (quote): "Supported by grants from the Fondo de Investigacio´n Sanitaria
 




Trial name/trial registry number: not stated
 




Bias	 Authors' judgement Support for judgement
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Low risk Comment: there were no post­randomisation dropouts. 
Selective reporting (re­
porting bias) 
Unclear risk Comment: pre­published protocol was not available. 











Post­randomisation dropouts: 0 (0.0%)
 
Revised sample size: 24
 




Ascites grade 2: 0 (0.0%)
 
Ascites grade 3: 24 (100.0%)
 
Refractory or recurrent ascites: not stated
 
Alcohol­related cirrhosis: not stated
 
Viral­related cirrhosis: not stated
 
Autoimmune disease­related cirrhosis: not stated
 
Other causes for cirrhosis: not stated
 






Interventions	 Group 1: Paracentesis plus reinfusion (n = 12)
 
Further details: Large volume paracentesis + apheresis and reinfusion of concentrated ascites (Al­

busave BT 902 or Hemofilter Pan 15)
 
Group 2: Paracentesis plus fluid replacement (n = 12)
 
Further details: Large volume paracentesis + albumin 6 g/litre of ascites removed
 
Outcomes	 Outcomes reported: mortality at maximal follow­up, liver transplantation at maximal follow­up, resolu­





Notes	 Source of funding (quote): "We would like to thank Mr. Libero Barbieri and Dr. Leonardo Bigi from Dide­

co Co., Mirandola, Modena, Italy, for their expert technical assistance".
 
Trial name/trial registry number: not stated
 




Bias	 Authors' judgement Support for judgement
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Graziotto 1997  (Continued) 
Random sequence genera­
tion (selection bias) 
Unclear risk Comment: this information was not available. 
Allocation concealment 
(selection bias) 













Low risk Comment: there were no post­randomisation dropouts. 
Selective reporting (re­
porting bias) 
Unclear risk Comment: pre­published protocol was not available. 











Post­randomisation dropouts: 0 (0.0%)
 
Revised sample size: 43
 




Ascites grade 2: not stated
 
Ascites grade 3: not stated
 








Other causes for cirrhosis: 0 (0.0%)
 
Prophylactic antibiotics for subacute bacterial peritonitis: not stated
 




Group 2: Aldosterone antagonists plus loop diuretics (n = 22)
 
Further details: Spironolactone 100 to 400 mg/day and furosemide 40 mg/day oral and then increased
 










Notes	 Source of funding: not stated
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Gregory 1977  (Continued) 
Trial name/trial registry number: not stated 
Attempts were made to contact the authors in November 2018. 
Risk of bias 
Bias Authors' judgement Support for judgement 
Random sequence genera­
tion (selection bias) 
Unclear risk Comment: this information was not available. 
Allocation concealment 
(selection bias) 













Low risk Comment: there were no post­randomisation dropouts. 
Selective reporting (re­
porting bias) 
Unclear risk Comment: pre­published protocol was not available. 











Post­randomisation dropouts: not stated
 
Revised sample size: 53
 




Ascites grade 2: not stated
 
Ascites grade 3: not stated
 




Viral­related cirrhosis: not stated
 
Autoimmune disease­related cirrhosis: not stated
 
Other causes for cirrhosis: not stated
 








Interventions Group 1: Aldosterone antagonists plus loop diuretics (n = 27)
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Hagege 1992  (Continued) 
Further details: Spironolactone 225 to 300 mg/day and furosemide 40 mg to 80/day oral , duration not 
stated ­ probably until follow­up 
Group 2: Paracentesis plus fluid replacement (n = 26) 
Further details: paracentesis up to 4 litres/day + albumin 10 g/litre of ascites removed 
Outcomes Outcomes reported: mortality at maximal follow­up, serious adverse events (number of people), any 
adverse events (number of people), liver transplantation at maximal follow­up, resolution of ascites at 
maximal follow­up (by ultrasound), other features of decompensation at maximal follow­up, length of 
hospital stay (days) (all admissions until maximal follow­up) 
Follow­up (months): 3 
Notes Source of funding: not stated 
Trial name/trial registry number: not stated 
Attempts were made to contact the authors in November 2018. 
Risk of bias 
Bias Authors' judgement Support for judgement 
Random sequence genera­ Low risk Quote: "The treatment was designated by random draw". 
tion (selection bias) 
Allocation concealment Low risk Quote: "The treatment was designated by random draw". 
(selection bias) 




Blinding of outcome as­ High risk Quote: "No blinding (author replies)" 
sessment (detection bias) 
All outcomes 
Incomplete outcome data Unclear risk Quote: "there were patients excluded after randomization (author replies)". 
(attrition bias)  Comment: there were post­randomisation dropouts; it was not clear whether 
All outcomes they were related to intervention or outcomes. 
Selective reporting (re­ Low risk Comment: a pre­published protocol was not available, but the important out­
porting bias) comes were reported or obtained by email. 











Post­randomisation dropouts: not stated
 
Revised sample size: 50
 




Ascites grade 2: 0 (0.0%)
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Alcohol­related cirrhosis: not stated
 
Viral­related cirrhosis: not stated
 
Autoimmune disease­related cirrhosis: not stated
 
Other causes for cirrhosis: not stated
 








Interventions Group 1: Paracentesis plus systemic vasoconstrictors (n = 25) 
Further details: Large volume paracentesis + midodrine 12.5 mg TDS for 3 days 
Group 2: Paracentesis plus fluid replacement (n = 25) 
Further details: Large volume paracentesis + albumin 8 g/litre of ascites removed 
Outcomes Outcomes reported: treatment costs 
Follow­up (months): 0.25 
Notes Source of funding (quote): "The authors declare that they have nothing to disclose". 
Trial name/trial registry number: not stated 
Attempts were made to contact the authors in November 2018. 
Risk of bias 
Bias Authors' judgement Support for judgement 
Random sequence genera­ Unclear risk Comment: this information was not available. 
tion (selection bias) 
Allocation concealment Unclear risk Comment: this information was not available. 
(selection bias) 




Blinding of outcome as­ Unclear risk Comment: this information was not available. 
sessment (detection bias) 
All outcomes 
Incomplete outcome data Unclear risk Comment: this information was not available. 
(attrition bias) 
All outcomes 
Selective reporting (re­ Unclear risk Comment: pre­published protocol was not available. 
porting bias) 
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Post­randomisation dropouts: not stated
 
Revised sample size: 49
 




Ascites grade 2: 0 (0.0%)
 
Ascites grade 3: 49 (100.0%)
 




Viral­related cirrhosis: not stated
 
Autoimmune disease­related cirrhosis: not stated
 
Other causes for cirrhosis: not stated
 






2. Ischaemic heart disease
 
Interventions	 Group 1: Paracentesis plus systemic vasoconstrictors (n = 24)
 
Further details: Large volume paracentesis + terlipressin 1 mg every 4 hours for 2 days
 
Group 2: Paracentesis plus fluid replacement (n = 25)
 
Further details: Large volume paracentesis + albumin 8 g/litre of ascites removed
 






Notes	 Source of funding: not stated
 
Trial name/trial registry number: not stated
 




Bias	 Authors' judgement Support for judgement
 
































Other bias	 Low risk Comment: no other bias noted
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Post­randomisation dropouts: not stated
 
Revised sample size: 25
 




Ascites grade 2: not stated
 










Other causes for cirrhosis: 0 (0.0%)
 














ed to a diameter of 10 mm
 
Group 2: Paracentesis plus fluid replacement (n = 12)
 
Further details: Large volume paracentesis + albumin, no further details
 






Notes	 Source of funding: not stated
 
Trial name/trial registry number: not stated
 




Bias	 Authors' judgement Support for judgement
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Unclear risk Comment: this information was not available. 
Selective reporting (re­
porting bias) 
Unclear risk Comment: pre­published protocol was not available. 




Participants Country: Italy 
Period of recruitment: 2002­2007 
Number randomised: 84 
Post­randomisation dropouts: 0 (0.0%) 
Revised sample size: 84 
Average age (years): 64 
Females: 31 (36.9%) 
Ascites grade 2: not stated 





Other causes for cirrhosis: 1 (1.2%) 
Prophylactic antibiotics for subacute bacterial peritonitis: not stated 
Exclusion criteria 
1. Other features of decompensation 
2. Heart failure 
3. Hepatocellular carcinoma 
Interventions Group 1: Loop diuretics (n = 60) 
Further details: High dose furosemide 250 mg to 1000 mg BD until 3 days before discharge along with 
hypertonic saline infusion 
Group 2: Aldosterone antagonists plus loop diuretics + paracentesis plus fluid replacement (n = 24) 
Further details: Repeated paracentesis removing 4 to 6 litres per day + albumin 5 to 8 g/litre removed + 
spironolactone 400 mg/day + furosemide up to 160 mg/day until 3 days before discharge 
Outcomes Outcomes reported: mortality at maximal follow­up, resolution of ascites at maximal follow­up (by ul­
trasound), other features of decompensation at maximal follow­up, length of hospital stay (days) (all 
admissions until maximal follow­up) 
Follow­up (months): 0.3 
Notes Source of funding (quote): "Declaration of personal and funding interests: None" 
Trial name/trial registry number: not stated 
Attempts were made to contact the authors in November 2018. 
Risk of bias 
Bias Authors' judgement Support for judgement 
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Licata 2009  (Continued) 
Random sequence genera­
tion (selection bias) 
Low risk Quote: "Patients were randomly assigned by the use of sequentially numbered 




Low risk Quote: "Patients were randomly assigned by the use of sequentially numbered 














Low risk Comment: there were no post­randomisation dropouts. 
Selective reporting (re­
porting bias) 
Unclear risk Comment: pre­published protocol was not available. 











Post­randomisation dropouts: not stated
 
Revised sample size: 21
 




Ascites grade 2: 0 (0.0%)
 
Ascites grade 3: 21 (100.0%)
 








Other causes for cirrhosis: not stated
 
Prophylactic antibiotics for subacute bacterial peritonitis: not stated
 
Interventions	 Group 1: Aldosterone antagonists plus loop diuretics + paracentesis plus fluid replacement (n = 10)
 
Further details: Large volume paracentesis removing 5 to 6 litres + albumin 6 to 8 g/litre removed +
 
spironolactone 200 mg/day + furosemide up to 40 to 80 mg/day stepped treatment duration not re­

ported probably for the follow­up period
 
Group 2: Aldosterone antagonists plus loop diuretics (n = 11)
 
Further details: Spironolactone 200 mg/day + furosemide up to 40 to 80 mg/day stepped treatment du­

ration not reported probably for the follow­up period
 
Outcomes	 Outcomes reported: mortality at maximal follow­up, serious adverse events (number of people)
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Notes Source of funding: not stated 
Trial name/trial registry number: not stated 
Attempts were made to contact the authors in November 2018. 
Risk of bias 
Bias Authors' judgement Support for judgement 
Random sequence genera­
tion (selection bias) 
Low risk Quote: "On the third day of admission, patients were randomly allocated to 
two groups (random number table)". 
Allocation concealment 
(selection bias) 













Unclear risk Comment: some patients were excluded, but it was not clear whether they 
were excluded pre­randomisation or post­randomisation. 
Selective reporting (re­
porting bias) 
Unclear risk Comment: pre­published protocol was not available. 











Post­randomisation dropouts: not stated
 
Revised sample size: 21
 




Ascites grade 2: not stated
 
Ascites grade 3: not stated
 
Refractory or recurrent ascites: not stated
 
Alcohol­related cirrhosis: not stated
 
Viral­related cirrhosis: not stated
 
Autoimmune disease­related cirrhosis: not stated
 
Other causes for cirrhosis: not stated
 
Prophylactic antibiotics for subacute bacterial peritonitis: not stated
 
Interventions Group 1: Thiazide diuretics (n = 11)
 
Further details: hydrochlorothiazide 50 mg oral daily for 3 days
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Mchutchison 1989  (Continued) 
Group 2: Loop diuretics (n = 10) 
Further details: furosemide 240 mg oral daily for 3 days 
Additional details: The intervention and control numbers were not reported. 
Outcomes None of the outcomes of interest were reported. 
Notes Source of funding: not stated 
Trial name/trial registry number: not stated 
Attempts were made to contact the authors in November 2018. 
Risk of bias 
Bias Authors' judgement Support for judgement 
Random sequence genera­ Unclear risk Comment: this information was not available. 
tion (selection bias) 
Allocation concealment Unclear risk Comment: this information was not available. 
(selection bias) 




Blinding of outcome as­ Unclear risk Comment: this information was not available. 
sessment (detection bias) 
All outcomes 
Incomplete outcome data Unclear risk Comment: this information was not available. 
(attrition bias) 
All outcomes 
Selective reporting (re­ Unclear risk Comment: pre­published protocol was not available. 
porting bias) 











Post­randomisation dropouts: not stated
 
Revised sample size: 20
 




Ascites grade 2: not stated
 
Ascites grade 3: not stated
 




Viral­related cirrhosis: not stated
 
Autoimmune disease­related cirrhosis: not stated
 
Other causes for cirrhosis: not stated
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Mehta 1998  (Continued) 





Interventions Group 1: Paracentesis plus reinfusion (n = 10) 
Further details: Large volume paracentesis + haemodialysis and reinfusion 
Group 2: Paracentesis plus fluid replacement (n = 10) 
Further details: Large volume paracentesis + polymerised gelatin haemaccel 150 mL/litre of ascites re­
moved 
Outcomes Outcomes reported: treatment costs 
Follow­up (months): 3 
Notes Source of funding: not stated 
Trial name/trial registry number: not stated 
Attempts were made to contact the authors in November 2018. 
Risk of bias 
Bias Authors' judgement Support for judgement 
Random sequence genera­ Unclear risk Comment: this information was not available. 
tion (selection bias) 
Allocation concealment Unclear risk Comment: this information was not available. 
(selection bias) 




Blinding of outcome as­ High risk Quote: "open" 
sessment (detection bias) 
All outcomes 
Incomplete outcome data Unclear risk Comment: this information was not available. 
(attrition bias) 
All outcomes 
Selective reporting (re­ Unclear risk Comment: pre­published protocol was not available. 
porting bias) 











Post­randomisation dropouts: 4 (16.7%)
 
Revised sample size: 20
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Ascites grade 2: 0 (0.0%)
 
Ascites grade 3: 20 (100.0%)
 








Other causes for cirrhosis: 0 (0.0%)
 








Interventions	 Group 1: Paracentesis plus systemic vasoconstrictors (n = 10)
 




Group 2: Paracentesis plus fluid replacement (n = 10)
 










Notes	 Source of funding: not stated
 
Trial name/trial registry number: not stated
 




Bias	 Authors' judgement Support for judgement
 






















Incomplete outcome data Unclear risk Comment: there were post­randomisation dropouts. at least one of them
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Post­randomisation dropouts: 0 (0.0%)
 
Revised sample size: 60
 




Ascites grade 2: not stated
 








Autoimmune disease­related cirrhosis: not stated
 
Other causes for cirrhosis: not stated
 










Interventions	 Group 1: Transjugular intrahepatic portosystemic shunt (n = 30)
 
Further details: Transjugular intrahepatic portosystemic shunt (expandable stent) ­ initially dilated to 6
 
to 8 mm and further dilated to 8 mm to 10 mm depending upon portoSystemic pressure gradient
 
Group 2: Paracentesis plus fluid replacement (n = 30)
 
Further details: Large volume paracentesis + albumin 6 g/litre of ascites removed
 
Outcomes	 Outcomes reported: mortality at maximal follow­up, serious adverse events (number of people), any
 
adverse events (number of people), liver transplantation at maximal follow­up, resolution of ascites at
 




Notes	 Source of funding: not stated
 
Trial name/trial registry number: not stated
 




Bias	 Authors' judgement Support for judgement
 
Random sequence genera­ Low risk Quote: "Randomization was performed by selecting an opaque sealed enve­

tion (selection bias) lope that was numbered according to a random number table".
 
Allocation concealment Low risk Quote: "Randomization was performed by selecting an opaque sealed enve­

(selection bias) lope that was numbered according to a random number table".
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Low risk Comment: there were no post­randomisation dropouts. 
Selective reporting (re­
porting bias) 
Unclear risk Comment: pre­published protocol was not available. 







Post­randomisation dropouts: 0 (0.0%) 
Revised sample size: 25 
Average age (years): 48 
Females: 6 (24.0%) 
Ascites grade 2: not stated 





Other causes for cirrhosis: 3 (12.0%) 





Interventions Group 1: Aldosterone antagonists plus loop diuretics + systemic vasoconstrictors + paracentesis plus 
fluid replacement (n = 13) 
Further details: Spironolactone 100 to 400 mg/day + furosemide 40 to 160 mg/day + midodrine 7.5 mg 
TDS for 3 months + large volume paracentesis + albumin 8 g/litre of ascites removed 
Group 2: Aldosterone antagonists plus loop diuretics + paracentesis plus fluid replacement (n = 12) 
Further details: Spironolactone 100 to 400 mg/day + furosemide 40 to 160 mg/day + large volume para­
centesis + albumin 8 g/litre of ascites removed 
Outcomes Outcomes reported: mortality at maximal follow­up, serious adverse events (number of people), any 
adverse events (number of events), liver transplantation at maximal follow­up, resolution of ascites at 
maximal follow­up (by ultrasound), other features of decompensation at maximal follow­up 
Follow­up (months): 3 
Notes Source of funding (quote): "Funding information: None"
 
Trial name/trial registry number: NCT02173288
 
Attempts were made to contact the authors in November 2018.
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Bias Authors' judgement Support for judgement 
Random sequence genera­
tion (selection bias) 
Low risk Quote: "The randomization sequence was computer­generated and the alloca­
tion was concealed in opaque sealed envelopes". 
Allocation concealment 
(selection bias) 
Low risk Quote: "The randomization sequence was computer­generated and the alloca­















Low risk Comment: there were no post­randomisation dropouts. 
Selective reporting (re­
porting bias) 
Unclear risk Comment: pre­published protocol was not available. 











Post­randomisation dropouts: not stated
 
Revised sample size: 60
 




Ascites grade 2: not stated
 










Other causes for cirrhosis: 3 (5.0%)
 








Interventions	 Group 1: Osmotic diuretics (n = 30)
 




Group 2: No active treatment (n = 30)
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Raza 2011  (Continued) 
Further details: placebo 
Outcomes Outcomes reported: serious adverse events (number of people) 
Follow­up (months): 0.2 
Notes Source of funding: not stated 
Trial name/trial registry number: not stated 
Attempts were made to contact the authors in November 2018. 
Risk of bias 
Bias Authors' judgement Support for judgement 
Random sequence genera­
tion (selection bias) 
Unclear risk Comment: this information was not available. 
Allocation concealment 
(selection bias) 





Low risk Quote: "It was a double­blind trial, so that neither the patient nor the observer 




Low risk Quote: "It was a double­blind trial, so that neither the patient nor the observer 




Unclear risk Comment: this information was not available. 
Selective reporting (re­
porting bias) 
Unclear risk Comment: pre­published protocol was not available. 











Post­randomisation dropouts: 0 (0.0%)
 
Revised sample size: 100
 




Ascites grade 2: 65 (65.0%)
 
Ascites grade 3: 35 (35.0%)
 








Other causes for cirrhosis: 19 (19.0%)
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Romanelli 2006  (Continued) 
Prophylactic antibiotics for subacute bacterial peritonitis: not stated 
Interventions Group 1: Aldosterone antagonists plus loop diuretics + albumin (n = 54) 
Further details: Albumin 25 mg/day IV weekly for first year and after that, the same once every 2 weeks 
+ spironolactone 100 mg to 400 mg/day and furosemide 25 mg to 150 mg/day for duration of follow­up 
Group 2: Aldosterone antagonists plus loop diuretics (n = 46) 
Further details: Spironolactone 100 mg to 400 mg/day and furosemide 25 mg to 150 mg/day for dura­
tion of follow­up 
Outcomes Outcomes reported: mortality at maximal follow­up, liver transplantation at maximal follow­up, resolu­
tion of ascites at maximal follow­up (by ultrasound), other features of decompensation at maximal fol­
low­up 
Follow­up (months): 84 
Notes Source of funding (quote): "Supported by grants from the Italian Ministry of Education, University and 
Research and the University of Florence, Italy" 
Trial name/trial registry number: not stated 
Attempts were made to contact the authors in November 2018. 
Risk of bias 
Bias Authors' judgement Support for judgement 
Random sequence genera­ Low risk Quote: "Allocation schedule was generated using a computed random number 
tion (selection bias) generation system". 
Allocation concealment Low risk Quote: "using sealed envelopes containing the treatment assignments" 
(selection bias) 




Blinding of outcome as­ Unclear risk Comment: this information was not available. 
sessment (detection bias) 
All outcomes 
Incomplete outcome data Low risk Comment: there were no post­randomisation dropouts. 
(attrition bias) 
All outcomes 
Selective reporting (re­ Unclear risk Comment: pre­published protocol was not available. 
porting bias) 











Post­randomisation dropouts: 0 (0.0%)
 
Revised sample size: 60
 
Average age (years): 60
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Ascites grade 2: 0 (0.0%)
 






Viral­related cirrhosis: not stated
 
Autoimmune disease­related cirrhosis: not stated
 
Other causes for cirrhosis: not stated
 








Interventions Group 1: Transjugular intrahepatic portosystemic shunt (n = 29) 
Further details: Transjugular intrahepatic portosystemic shunt (expandable stent: Palmaz–Schatz stent 
or a self­expandable nitinol stent (Memotherm)) 
Group 2: Paracentesis plus fluid replacement (n = 31) 
Further details: Large volume paracentesis + albumin 8 g/litre of ascites removed 
Outcomes Outcomes reported: mortality at maximal follow­up, liver transplantation at maximal follow­up, other 
features of decompensation at maximal follow­up, length of hospital stay (days) (all admissions until 
maximal follow­up) 
Follow­up (months): 44.5 
Notes Source of funding: not stated 
Trial name/trial registry number: not stated 
Attempts were made to contact the authors in November 2018. 
Risk of bias 
Bias Authors' judgement Support for judgement 
Random sequence genera­ Unclear risk Comment: this information was not available. 
tion (selection bias) 
Allocation concealment Unclear risk Comment: this information was not available. 
(selection bias) 




Blinding of outcome as­ Unclear risk Comment: this information was not available. 
sessment (detection bias) 
All outcomes 
Incomplete outcome data Low risk Comment: there were no post­randomisation dropouts. 
(attrition bias) 
All outcomes 
Selective reporting (re­ Unclear risk Comment: pre­published protocol was not available. 
porting bias) 
Other bias Low risk Comment: no other bias noted 
Treatment for ascites in adults with decompensated liver cirrhosis: a network meta­analysis (Review)
 














       
       
         
         
             
                 
                           
           
               
                                 
 
                       
                           
       
         
                 
   
         
         
         
         
 
                       


















Post­randomisation dropouts: 0 (0.0%)
 
Revised sample size: 41
 




Ascites grade 2: 0 (0.0%)
 
Ascites grade 3: 41 (100.0%)
 








Other causes for cirrhosis: 9 (22.0%)
 








Interventions	 Group 1: Aldosterone antagonists plus loop diuretics (n = 21)
 
Further details: Spironolactone 200 to 400 mg/day and furosemide 50 mg/day oral added as necessary,
 
duration not stated ­ probably until follow­up
 
Group 2: Paracentesis plus fluid replacement (n = 20)
 




Outcomes	 Outcomes reported: mortality at maximal follow­up, serious adverse events (number of events), resolu­







Notes	 Source of funding: not stated
 
Trial name/trial registry number: not stated
 




Bias	 Authors' judgement Support for judgement
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Low risk Comment: there were no post­randomisation dropouts. 
Selective reporting (re­
porting bias) 
Unclear risk Comment: pre­published protocol was not available. 











Post­randomisation dropouts: 0 (0.0%)
 
Revised sample size: 66
 




Ascites grade 2: not stated
 








Autoimmune disease­related cirrhosis: not stated
 
Other causes for cirrhosis: not stated
 








Interventions	 Group 1: Transjugular intrahepatic portosystemic shunt (n = 33)
 




Group 2: Paracentesis plus fluid replacement (n = 33)
 
Further details: Large volume paracentesis + albumin 8 g/litre of ascites removed
 
Outcomes	 Outcomes reported: mortality at maximal follow­up, liver transplantation at maximal follow­up, resolu­

tion of ascites at maximal follow­up (by ultrasound), other features of decompensation at maximal fol­









Trial name/trial registry number: not stated
 




Bias	 Authors' judgement Support for judgement
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Low risk Comment: there were no post­randomisation dropouts. 
Selective reporting (re­
porting bias) 
Unclear risk Comment: pre­published protocol was not available. 











Post­randomisation dropouts: 0 (0.0%)
 
Revised sample size: 109
 




Ascites grade 2: not stated
 








Autoimmune disease­related cirrhosis: not stated
 
Other causes for cirrhosis: not stated
 




1. Conditions likely to limit life expectance to < 1 year
 




Interventions	 Group 1: Transjugular intrahepatic portosystemic shunt (n = 52)
 




Group 2: Paracentesis plus fluid replacement (n = 57)
 
Further details: Large volume paracentesis + albumin 6 to 8 g/litre of ascites removed
 
Outcomes	 Outcomes reported: mortality at maximal follow­up, liver transplantation at maximal follow­up, resolu­
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Library Better health. Cochrane Database of Systematic Reviews
 
Sanyal 2003  (Continued) 
Follow­up (months): 12 
Notes Source of funding (quote): "Supported by grant RO1 DK 51523 from the National Institutes of Health (to 
A.J.S.) and MO1­RR­00065" 
Trial name/trial registry number: NASTRA 
Attempts were made to contact the authors in November 2018. 
Risk of bias 
Bias Authors' judgement Support for judgement 
Random sequence genera­
tion (selection bias) 
Unclear risk Comment: this information was not available. 
Allocation concealment 
(selection bias) 
Low risk Quote: "Subjects were then randomized centrally to either the medical thera­
py arm (defined by restriction of sodium, treatment with diuretics, and repeat­













Low risk Comment: there were no post­randomisation dropouts. 
Selective reporting (re­
porting bias) 
Unclear risk Comment: pre­published protocol was not available. 











Post­randomisation dropouts: 3 (15.0%)
 
Revised sample size: 17
 
Reasons for post­randomisation dropouts: not stated
 




Ascites grade 2: not stated
 
Ascites grade 3: not stated
 






Autoimmune disease­related cirrhosis: not stated
 
Other causes for cirrhosis: not stated
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Library Better health. Cochrane Database of Systematic Reviews
 
Schaub 1995  (Continued) 
Prophylactic antibiotics for subacute bacterial peritonitis: not stated 
Interventions Group 1: Aldosterone antagonists plus loop diuretics (n = 9) 
Further details: Spironolactone 200 mg/day + furosemide 40 mg/day, duration not stated 
Group 2: Paracentesis plus fluid replacement (n = 8) 
Further details: Large volume paracentesis over 2 days + albumin 60 g for each puncture 
Outcomes Outcomes reported: length of hospital stay (days) (all admissions until maximal follow­up) 
Follow­up (months): 0.75 
Notes Source of funding: not stated 
Trial name/trial registry number: not stated 
Attempts were made to contact the authors in November 2018. 
Risk of bias 
Bias Authors' judgement Support for judgement 
Random sequence genera­ Unclear risk Comment: this information was not available. 
tion (selection bias) 
Allocation concealment Unclear risk Comment: this information was not available. 
(selection bias) 




Blinding of outcome as­ Unclear risk Comment: this information was not available. 
sessment (detection bias) 
All outcomes 
Incomplete outcome data Unclear risk Comment: there were post­randomisation dropouts but the reasons were not 
(attrition bias)  reported; therefore, it was difficult to judge whether this would have led to bi­
All outcomes ased treatment effect. 
Selective reporting (re­ Unclear risk Comment: pre­published protocol was not available. 
porting bias) 











Post­randomisation dropouts: 0 (0.0%)
 
Revised sample size: 40
 




Ascites grade 2: 0 (0.0%)
 
Ascites grade 3: 40 (100.0%)
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Other causes for cirrhosis: 7 (17.5%) 




Interventions Group 1: Paracentesis plus systemic vasoconstrictors (n = 20) 
Further details: Total paracentesis + noradrenaline 0.5 mg/hr titrated to maintain mean arterial pres­
sure about 10 mmHg above baseline for 72 hours 
Group 2: Paracentesis plus fluid replacement (n = 20) 
Further details: Total paracentesis + albumin (8 g/L of removed ascites) 
Outcomes Outcomes reported: mortality at maximal follow­up, serious adverse events (number of people), any 
adverse events (number of people), liver transplantation at maximal follow­up, treatment costs 
Follow­up (months): 0.25 
Notes Source of funding (quote): "No major funding. If patients were unable to purchase medications, we as­
sisted them and they were provided medications (author replies)". 
Trial name/trial registry number: not stated 
Attempts were made to contact the authors in November 2018. 
Risk of bias 
Bias Authors' judgement Support for judgement 
Random sequence genera­ Low risk Quote: "computer­generated (author replies)" 
tion (selection bias) 
Allocation concealment Low risk Quote: "opaque sealed envelopes (author replies)" 
(selection bias) 




Blinding of outcome as­ High risk Quote: "No blinding (author replies)" 
sessment (detection bias) 
All outcomes 
Incomplete outcome data Low risk Comment: there were no post­randomisation dropouts. 
(attrition bias) 
All outcomes 
Selective reporting (re­ Low risk Comment: a pre­published protocol was not available, but the important out­
porting bias) comes were reported or obtained by email. 
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Post­randomisation dropouts: 3 (7.0%) 
Revised sample size: 40 
Reasons for post­randomisation dropouts: GI bleed, abdominal tuberculosis 
Average age (years): 47 
Females: 4 (10.0%) 
Ascites grade 2: 0 (0.0%) 
Ascites grade 3: 40 (100.0%) 




Prophylactic antibiotics for subacute bacterial peritonitis: not stated 




Interventions Group 1: Paracentesis plus systemic vasoconstrictors (n = 20) 
Further details: Total paracentesis + terlipressin 1 mg at 0, 8, and 16 hours of paracentesis 
Group 2: Paracentesis plus fluid replacement (n = 20) 
Further details: Total paracentesis + albumin (8 g/L of removed ascites) 
Outcomes Outcomes reported: mortality at maximal follow­up, serious adverse events (number of people), any 
adverse events (number of people), liver transplantation at maximal follow­up 
Follow­up (months): 0.25 
Notes Source of funding (quote): "No major funding. If patients were unable to purchase medications, we as­
sisted them and they were provided medications (author replies)". 
Trial name/trial registry number: not stated 
Attempts were made to contact the authors in November 2018. 
Risk of bias 
Bias Authors' judgement Support for judgement 
Random sequence genera­
tion (selection bias) 
Low risk Quote: "computer­generated (author replies)" 
Allocation concealment 
(selection bias) 













Unclear risk Comment: there were post­randomisation dropouts, but it was not clear 
whether these could be related to the intervention or outcomes. 
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Low risk Comment: a pre­published protocol was not available, but the important out­
comes were reported or obtained by email. 











Post­randomisation dropouts: 0 (0.0%)
 
Revised sample size: 40
 




Ascites grade 2: 0 (0.0%)
 
Ascites grade 3: 40 (100.0%)
 


















Interventions	 Group 1: Paracentesis plus systemic vasoconstrictors (n = 20)
 
Further details: Total paracentesis + midodrine 5 to 10 mg TDS for 72 hours
 
Group 2: Paracentesis plus fluid replacement (n = 20)
 
Further details: Total paracentesis + albumin (8 g/L of removed ascites)
 
Outcomes	 Outcomes reported: mortality at maximal follow­up, serious adverse events (number of people), any
 
adverse events (number of people), liver transplantation at maximal follow­up, other features of de­





Notes	 Source of funding (quote): "Financial support: None"
 
Trial name/trial registry number: not stated
 




Bias	 Authors' judgement Support for judgement
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Low risk Comment: there were no post­randomisation dropouts. 
Selective reporting (re­
porting bias) 
Low risk Comment: a pre­published protocol was not available, but the important out­
comes were reported or obtained by email. 











Post­randomisation dropouts: 0 (0.0%)
 
Revised sample size: 40
 




Ascites grade 2: not stated
 










Other causes for cirrhosis: 0 (0.0%)
 






Years of recruitment: 2007­2009
 
Interventions	 Group 1: Aldosterone antagonists plus loop diuretics + systemic vasoconstrictors (n = 20)
 
Further details: Spironolactone 100 to 400 mg/day + furosemide 40 to 160 mg/day + midodrine 7.5 mg
 
TDS oral for a mean of 2 months
 
Group 2: Aldosterone antagonists plus loop diuretics (n = 20)
 
Further details: Spironolactone 100 to 400 mg/day + furosemide 40 to 160 mg/day, duration not stated
 
Outcomes	 Outcomes reported: mortality at maximal follow­up, serious adverse events (number of people), liver
 




Notes	 Source of funding (quote): "The authors who have taken part in this study declared that they do not
 
have anything to disclose regarding funding or conflict of interest with respect to this manuscript".
 
Trial name/trial registry number: not stated
 




Treatment for ascites in adults with decompensated liver cirrhosis: a network meta­analysis (Review)
 








       
   
           
           
                 
               
                 
               
           
                     








       
       
         
             
                       
                               
                               
                       
                               
                 
 
                       






Library Better health. Cochrane Database of Systematic Reviews
 
Singh 2012a  (Continued) 
Bias Authors' judgement Support for judgement 
Random sequence genera­
tion (selection bias) 
Low risk Quote: "A computer made randomization code" 
Allocation concealment 
(selection bias) 





Unclear risk Quote: "Patients and investigators were blinded to the treatment assign­
ments". 




Unclear risk Quote: "Patients and investigators were blinded to the treatment assign­
ments". 




Low risk Comment: there were no post­randomisation dropouts. 
Selective reporting (re­
porting bias) 
Low risk Comment: a pre­published protocol was not available, but the important out­
comes were reported or obtained by email. 











Post­randomisation dropouts: 0 (0.0%)
 
Revised sample size: 60
 




Ascites grade 2: not stated
 










Other causes for cirrhosis: 5 (8.3%)
 










Further details: Spironolactone 100 to 400 mg/day + furosemide 40 to 160 mg/day + midodrine 7.5 mg
 
TDS oral + clonidine 0.1 mg BD or both until endpoints were reached ­ probably 1 month
 
Group 2: Aldosterone antagonists plus loop diuretics + systemic vasoconstrictors (n = 15)
 
Further details: Spironolactone 100 to 400 mg/day + furosemide 40 to 160 mg/day + midodrine 7.5 mg
 
TDS oral until endpoints were reached ­ probably 1 month
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Group 3: Aldosterone antagonists plus loop diuretics + systemic vasodilator (n = 15)
 
Further details: Spironolactone 100 to 400 mg/day + furosemide 40 to 160 mg/day + clonidine 0.1 mg
 
BD until endpoints were reached ­ probably 1 month
 
Group 4: Aldosterone antagonists plus loop diuretics (n = 15)
 
Further details: Spironolactone 100 to 400 mg/day + furosemide 40 to 160 mg/day duration until end­

points were reached ­ probably 1 month
 
Outcomes Outcomes reported: mortality at maximal follow­up, serious adverse events (number of people), any 
adverse events (number of events), liver transplantation at maximal follow­up, resolution of ascites at 
maximal follow­up (by ultrasound), other features of decompensation at maximal follow­up 
Follow­up (months): 1 
Notes Source of funding (quote): "Financial support: None" 
Trial name/trial registry number: not stated 
Attempts were made to contact the authors in November 2018. 
Risk of bias 
Bias Authors' judgement Support for judgement 
Random sequence genera­ Low risk Quote: "A computer made the randomization code with 60 envelopes, with 15 
tion (selection bias) patients in each group". 
Allocation concealment Low risk Quote: "A computer made the randomization code with 60 envelopes, with 15 
(selection bias) patients in each group". 




Blinding of outcome as­ High risk Quote: "Patients and investigators were not blinded to the treatment assign­
sessment (detection bias)  ments". 
All outcomes 
Incomplete outcome data Low risk Comment: there were no post­randomisation dropouts. 
(attrition bias) 
All outcomes 
Selective reporting (re­ Low risk Comment: a pre­published protocol was not available, but the important out­
porting bias) comes were reported or obtained by email. 











Post­randomisation dropouts: 9 (11.3%)
 
Revised sample size: 71
 
Reasons for post­randomisation dropouts: cross­over or lost to follow­up
 




Ascites grade 2: 0 (0.0%)
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Library Better health. Cochrane Database of Systematic Reviews
 
Sola 1994  (Continued) 
Ascites grade 3: 71 (100.0%) 
Refractory or recurrent ascites: not stated 
Alcohol­related cirrhosis: 63 (88.7%) 
Viral­related cirrhosis: not stated 
Autoimmune disease­related cirrhosis: not stated 
Other causes for cirrhosis: not stated 
Prophylactic antibiotics for subacute bacterial peritonitis: not stated 
Interventions Group 1: Aldosterone antagonists plus loop diuretics + paracentesis plus fluid replacement (n = 38) 
Further details: Total paracentesis + dextran­40 (8 g/L of removed ascites) + spironolactone 100 to 400 
mg/day + furosemide 40 to 240 mg/day; duration not reported, probably end of follow­up 
Group 2: Aldosterone antagonists plus loop diuretics (n = 33) 
Further details: Spironolactone 100 to 400 mg/day + furosemide 40 to 240 mg/day; duration not report­
ed, probably end of follow­up 
Outcomes Outcomes reported: mortality at maximal follow­up, other features of decompensation at maximal fol­
low­up 
Follow­up (months): 13 
Notes Source of funding (quote): "This work was supported by a grant from the Institut Municipal d'Investi­
gaci6 Medica (IMIM) IM 876413601." 
Trial name/trial registry number: not stated 
Attempts were made to contact the authors in November 2018. 
Risk of bias 
Bias Authors' judgement Support for judgement 
Random sequence genera­ Low risk Quote: "random number table" 
tion (selection bias) 
Allocation concealment Unclear risk Comment: this information was not available. 
(selection bias) 




Blinding of outcome as­ Unclear risk Comment: this information was not available. 
sessment (detection bias) 
All outcomes 
Incomplete outcome data Unclear risk Comment: there were post­randomisation dropouts, but it is not clear whether 
(attrition bias)  this could have led to biased treatment effects. 
All outcomes 
Selective reporting (re­ Unclear risk Comment: pre­published protocol was not available. 
porting bias) 
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Sola 2018  (Continued) 
Participants Country: Spain 
Period of recruitment: 2008­2015 
Number randomised: 196 
Post­randomisation dropouts: 23 (11.7%) 
Revised sample size: 173 
Reasons for post­randomisation dropouts: liver transplantation, death, incorrect randomisation, with­
drawal of consent 
Average age (years): 55 
Females: 36 (20.8%) 
Ascites grade 2: not stated 
Ascites grade 3: not stated 
Refractory or recurrent ascites: not stated 
Alcohol­related cirrhosis: 72 (41.6%) 
Viral­related cirrhosis: 80 (46.2%) 
Autoimmune disease­related cirrhosis: not stated 
Other causes for cirrhosis: not stated 
Prophylactic antibiotics for subacute bacterial peritonitis: both 
Other inclusion criteria 
1. Patients awaiting liver transplantation 
Interventions Group 1: Systemic vasoconstrictors + albumin (n = 87) 
Further details: Midodrine 5 mg TDS orally (increased up to 30 mg daily) + albumin IV 40 mg every 15 
days for 1 year 
Group 2: No active treatment (n = 86) 
Further details: placebo 
Outcomes Outcomes reported: mortality at maximal follow­up, serious adverse events (number of people), any 
adverse events (number of people), any adverse events (number of events), liver transplantation at 
maximal follow­up, other features of decompensation at maximal follow­up 
Follow­up (months): 11 
Notes Source of funding (quote): "No economic support was provided by the companies, except that Grifols 
S.A. (Spain) gave a donation to support the transport costs incurred by patients participating in the 
study". 
Trial name/trial registry number: NCT00839358 
Attempts were made to contact the authors in November 2018. 
Risk of bias 
Bias Authors' judgement Support for judgement 
Random sequence genera­
tion (selection bias) 
Low risk Quote: "A computer­generated…" 
Allocation concealment 
(selection bias) 











Low risk Quote: "All investigators and patients were blinded to treatment assignmen­
t..placebo". 
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High risk Comment: there were post­randomisation dropouts, which were probably re­
lated to intervention and outcomes. 
Selective reporting (re­
porting bias) 
Low risk Comment: a pre­published protocol was not available, but the important out­
comes were reported. 











Post­randomisation dropouts: 0 (0.0%)
 
Revised sample size: 299
 




Ascites grade 2: not stated
 
Ascites grade 3: not stated
 




Viral­related cirrhosis: not stated
 
Autoimmune disease­related cirrhosis: not stated
 
Other causes for cirrhosis: not stated
 
Prophylactic antibiotics for subacute bacterial peritonitis: not stated
 
Interventions	 Group 1: Peritoneovenous shunt (n = 146)
 
Further details: Le Veen shunt
 
Group 2: Aldosterone antagonists plus loop diuretics (n = 153)
 
Further details: spironolactone 100 to 400 mg/day + furosemide 40 to 320 mg/day
 
Outcomes	 None of the outcomes of interest were reported.
 




Trial name/trial registry number: not stated
 




Bias	 Authors' judgement Support for judgement
 




Allocation concealment Low risk Quote: "Each patient who consented to participate was assigned to a treat­
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Unclear risk Comment: there were no post­randomisation dropouts. 
Selective reporting (re­
porting bias) 
Unclear risk Comment: pre­published protocol was not available. 




Participants Country: Brazil 
Period of recruitment: 1995­1990 
Number randomised: 33 
Post­randomisation dropouts: 2 (6.1%) 
Revised sample size: 31 
Reasons for post­randomisation dropouts: death before starting treatment and diagnosed with HRS 
Average age (years): 52 
Females: 7 (22.6%) 
Ascites grade 2: not stated 




Autoimmune disease­related cirrhosis: not stated 
Other causes for cirrhosis: not stated 




Interventions Group 1: Aldosterone antagonists plus loop diuretics + paracentesis plus fluid replacement (n = 16) 
Further details: Repeated paracentesis + albumin (20 g paracentesis) + spironolactone 150 to 300 mg/ 
day + furosemide 40 to 80 mg/day; duration not reported, probably end of follow­up 
Group 2: Aldosterone antagonists plus loop diuretics (n = 15) 
Further details: Spironolactone 150 to 300 mg/day + furosemide 40 to 80 mg/day; duration not report­
ed, probably end of follow­up 
Outcomes Outcomes reported: resolution of ascites at maximal follow­up (by ultrasound), other features of de­
compensation at maximal follow­up 
Follow­up (months): 0.5 
Notes Source of funding: not stated 
Trial name/trial registry number: not stated 
Attempts were made to contact the authors in November 2018. 
Risk of bias
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Strauss 1991  (Continued) 
Bias Authors' judgement Support for judgement 
Random sequence genera­
tion (selection bias) 
Low risk Quote: "statistical table of random numbers" 
Allocation concealment 
(selection bias) 
Low risk Quote: "system of sealed envelopes, numbered successively, after the selec­














Unclear risk Comment: there were post­randomisation dropouts, but it was not clear 




Unclear risk Comment: pre­published protocol was not available. 











Post­randomisation dropouts: 0 (0.0%)
 
Revised sample size: 59
 




Ascites grade 2: not stated
 










Other causes for cirrhosis: not stated
 










Interventions	 Group 1: Loop diuretics (n = 31)
 




Group 2: Paracentesis plus fluid replacement (n = 28)
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Further details: Repeated paracentesis removing 4 to 6 litres per day + albumin 5 to 8 g/litre removed
 
Outcomes Outcomes reported: length of hospital stay (days) (all admissions until maximal follow­up) 
Follow­up (months): 0.3 
Notes Source of funding (quote): "Author(s) received no specific funding for this work". 
Trial name/trial registry number: NCT02821377 
Attempts were made to contact the authors in November 2018. 
Risk of bias 
Bias Authors' judgement Support for judgement 
Random sequence genera­
tion (selection bias) 
Unclear risk Comment: this information was not available. 
Allocation concealment 
(selection bias) 













Low risk Comment: there were no post­randomisation dropouts. 
Selective reporting (re­
porting bias) 
Unclear risk Comment: pre­published protocol was not available. 











LVP: large volume paracentesis
 






Characteristics of excluded studies [ordered by study ID]
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Reason for exclusion Study
 
Antillon 1993	 Not a randomised clinical trial
 
Applefeld 1994	 In this cross­over randomised clinical trial, the cross­over took place after 12 days of treatment
 
with just 2 days between the cross­over; this short duration of treatment and cross­over period is
 




Bories 1986 The diuretics used in the control group was variable ­ these may or may not have been used; there­

fore it is not possible to define the control group.
 
Bostan 2019	 Not a randomised clinical trial
 
Boyer 1983	 Not a randomised clinical trial
 
Brater 2001	 Not a randomised clinical trial
 
Bureau 2017a	 There were several differences between the intervention and control group: the antibiotic prophy­

laxis was given only to intervention group, the diuretics were stopped in the intervention but not in
 
the control group and this was variable; therefore, it was not possible to define the control group.
 
Cadranel 1992a The unit of randomisation was the procedure (i.e. each patient underwent both procedures).
 
Cadranel 1992b Not a randomised clinical trial
 








Fuller 1977	 In this cross­over randomised clinical trial, the cross­over took place after 6 days of treatment with
 
just 6 days between the cross­over; this short duration of treatment and cross­over period was in­

sufficient time to determine the objectives of this review.
 
Gadano 1997	 Atrial natriuretic peptide was given for sodium retention and not for treatment of ascites.
 
















Giostra 2000 No details of the diuretic regimen were available; so, it was not entirely clear if the drugs in the di­

uretic regimen were similar in the two groups.
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Reason for exclusion Study
 
He 2012 No details of the diuretic regimen were available; so, it was not entirely clear if the drugs in the di­

uretic regimen were similar in the two groups.
 




Inoue 1969 Not a randomised clinical trial
 
Kalambokis 2007 This trial included non­ascites people and the randomisation was not stratified by presence of as­

cites or separate data was not available in those with ascites.
 
Kalambokis 2008 Not a randomised clinical trial
 
Knauf 1994 In this short­term study, the patients who did not respond to one treatment crossed over to the
 
other treatment. Therefore, this design will not answer our objectives.
 
Krag 2007b The diuretics used in the intervention and control group was variable ­ these may or may not have
 
been used; therefore it was not possible to define the intervention or control group.
 
Krag 2008 The diuretics used in the intervention and control group was variable ­ these may or may not have
 
been used; therefore it was not possible to define the intervention or control group.
 
Kurt 2011 Not a randomised clinical trial
 
Laffi 1992 Not an intervention included in the systematic review
 
Laffi 2003 Not a randomised clinical trial
 
Lai 1991 In this short­term study, the patients who did not respond to one treatment crossed over to the
 
other treatment. Therefore, this design will not answer our objectives.
 
Leodolter 1972 Not a randomised clinical trial
 
Lieberman 1965 Not a randomised clinical trial
 
Lowenthal 1973 Not a randomised clinical trial
 
Luca 1995 Not an intervention included in the systematic review
 
Marra 1979 Quasi­randomised study (allocation by order of entry to ward)
 
Merino 1967 Not a randomised clinical trial
 






Nakamura 2014 Not an intervention included in the systematic review
 
Narahara 2009 The diuretic regimen was different in the two groups.
 
Perez 1983 After 5 days, if there was no response, patients crossed­over; this short duration of treatment and
 
cross­over period was insufficient time to determine the objectives of this review.
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Reason for exclusion Study
 
Perkins 2006 Not a randomised clinical trial 
Planas 1990 Comparison of variations in treatment 
Ring­Larsen 1988 The control group of diuretics was not defined; therefore it was not possible to assess whether the 
control group was defined. 
Roseau 2000 Not a randomised clinical trial 
Runyon 1989 The unit of randomisation was the procedures (i.e. some patients underwent both treatments). 
Sadikali 1973 Not a randomised clinical trial 
Salerno 1991 Comparison of variations in treatment 
Salerno 1997 Comparison of variations in treatment 
Santos 2003 After about 2 weeks, if there was no response, patients crossed over. 
Sarin 1988 Included patients without cirrhosis 
Sarti 1984 Not a randomised clinical trial 
Schmukler 1968 Not a randomised clinical trial 
Shafei 1967 Not a randomised clinical trial 
Sohn 2017 Included only patients who developed acute kidney failure following treatment 
Sola­Vera 2003 Comparison of variations in treatment 
Stanley 1989a Not a randomised clinical trial 
Steigmann 1966 Not a randomised clinical trial 
Tempini 1984 Comparison of variations in treatment 
Thompson 1977 In this cross­over trial, the wash­out period was only 3 days; this will not answer the objectives of 
this systematic review. 
Tsai 1996 Not a comparison of interest 
Vizzutti 2001 In the control group, the diuretic regimen was variable. 
Wapnick 1979 Appeared to be a quasi­randomised study or a nonrandomised study: authors stated "Patients in 
the medical group were matched with those in the surgical group according to the subgroups listed 
in Table I and sequentially according to the date of entry into the study". 
Yakar 2016 Although authors called this a randomised study, the authors also stated that the patients were 
studied retrospectively. An adequate method of randomisation was also not reported. 
Yamada 1970 Not a randomised clinical trial 
Yosry 2019 Quasi­randomised study (allocation by alternate assignment) 
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Reason for exclusion Study
 
Zaak 2001 Not a randomised clinical trial 
Zhang 2013 Not clear if all participants had cirrhosis 
Zhao 2000 Comparison of variations in treatment 








Outcomes 1. Transplant­free survival 
2. Overall survival 
3. Non­resolution of ascites 








Interventions Tunnelled peritoneal catheter versus paracentesis plus fluid replacement 
Outcomes 1. Overall survival 
2. Adverse events 
3. Health resource utilisation and quality of life 
Starting date 1 October 2015 
Contact information Lucia Macken (lucia.macken@bsuh.nhs.uk) 
Notes ISRCTN30697116 
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Interventions Tunnelled peritoneal catheter versus paracentesis plus fluid replacement 
Outcomes 1. Non­resolution of ascites 
2. Adverse events 
Starting date 20 January 2017 
Contact information Gastro Unit, Medical Division, University Hospital Hvidovre, Hvidovre, Denmark, 2650 







Outcomes 1. Transplant­free survival 
2. Hepatic decompensation 
3. Quality of life 
4. Adverse events 









Participants Grade 3 or refractory ascites and cirrhosis
 
Interventions Paracentesis plus fresh frozen plasma plus albumin versus paracentesis plus albumin
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NCT03202524  (Continued) 
Outcomes 1. Incidence of post­paracentesis circulatory dysfunction 
Starting date December 2017 
Contact information Montefiore Medical Center 







Outcomes 1. Treatment costs 
2. Non­resolution of ascites 
3. Hepatic decompensation 
4. Adverse events 





Table 1. Revised 'International Ascites Club' criteria for refractory ascites
 
1. Treatment duration: patients must be on intensive diuretic therapy (spironolactone 400 mg/day and furosemide 160 mg/day) for
 
at least 1 week and on a salt­restricted diet of less than 90 mmol or 5.2 g of salt/day
 
2. Lack of response: mean weight loss of less than 0.8 kg over 4 days and urinary sodium output less than the sodium intake
 






•	 Diuretic­induced renal impairment is an increase of serum creatinine by more than 100% to a value more than 2 mg/dL in patients
 
with ascites responding to treatment.
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Table 2. Characteristics of included studies and potential effect modifiers
 
This table is too wide to be displayed in RevMan. This table can be found at: https://doi.org/10.5281/zenodo.3604600.
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Table 3. Risk of bias
 
Study name Sequence Allocation con­ Blinding of pa­ Blinding of out­ Missing out­ Selective outcome Overall risk 
generation cealment tients and health­ come assessors come bias reporting of bias 
care providers 
Chang 1997 Low Unclear Unclear Unclear Unclear Unclear High 
Chesta 1990 Unclear Unclear Unclear Unclear Unclear Unclear High 
Gines 1987 Low Unclear Unclear Unclear Unclear Unclear High 
Hagege 1992 Low Low High High Unclear Low High 
Salerno 1987 Unclear Unclear Unclear Unclear Low Unclear High 
Schaub 1995 Unclear Unclear Unclear Unclear Unclear Unclear High 
Al Sebaey 2012 Unclear Unclear Unclear Unclear Unclear Unclear High 
Appenrodt 2008 Unclear Unclear Low Low Low Unclear High 
Bari 2012 Low Low Low Low Unclear Unclear High 
Hamdy 2014 Unclear Unclear Unclear Unclear Unclear Unclear High 
Lata 2007 Unclear Unclear Unclear Unclear Unclear Unclear High 
Moreau 2002 Unclear Unclear Unclear Unclear Unclear Unclear High 
Singh 2006a Low Low High High Low Low High 
Singh 2006b Low Low High High Unclear Low High 
Singh 2008 Low Low High High Low Low High 
Ljubici 1994 Low Unclear Unclear Unclear Unclear Unclear High 
Sola 1994 Low Unclear Unclear Unclear Unclear Unclear High 
Strauss 1991 Low Low Unclear Unclear Unclear Unclear High 



























































































































































































Table 3. Risk of bias  (Continued) 
Ginès 2002 Unclear Low Unclear Unclear Low Unclear High 
Lebrec 1996 Unclear Low Unclear Unclear Unclear Unclear High 
Narahara 2011 Low Low Unclear Unclear Low Unclear High 
Rossle 2000 Unclear Unclear Unclear Unclear Low Unclear High 
Salerno 2004 Unclear Low High High Low Unclear High 
Sanyal 2003 Unclear Low Unclear Unclear Low Unclear High 
Gregory 1977 Unclear Unclear Unclear Unclear Low Unclear High 
Tuttolomondo 2016 Unclear Unclear Unclear Unclear Low Unclear High 
Fogel 1981 Unclear Unclear High High Low Unclear High 
Licata 2009 Low Low Unclear Unclear Low Unclear High 
Bruno 1992 Low Low Unclear Unclear Low Unclear High 
Graziotto 1997 Unclear Low Unclear Unclear Low Unclear High 
Mehta 1998 Unclear Unclear High High Unclear Unclear High 
Gentilini 1999a Unclear Unclear Unclear Unclear Low Unclear High 
Romanelli 2006 Low Low Unclear Unclear Low Unclear High 
Caraceni 2018 Low Low High High Unclear High High 
Ginès 1991 Low Unclear Unclear Unclear Unclear Unclear High 
Ginès 1995 Unclear Unclear Unclear Unclear Unclear Unclear High 
Singh 2012a Low Low Unclear Unclear Low Low High 
Singh 2013 Low Low High High Low Low High 



























































































































































































Table 3. Risk of bias  (Continued) 
Acharya 1992 Unclear Unclear Unclear Unclear Unclear Unclear High 
Ali 2014 Low Low Low Low Unclear Low High 
Amin 2012 Unclear Unclear Unclear Unclear Unclear Unclear High 
Descos 1983 Unclear Unclear Unclear Unclear Unclear Unclear High 
Rai 2017 Low Low High High Low Unclear High 
Singh 2013 Low Low High High Low Low High 
Singh 2013 Low Low High High Low Low High 
Singh 2013 Low Low High High Low Low High 
Singh 2013 Low Low High High Low Low High 
Singh 2013 Low Low High High Low Low High 
Raza 2011 Unclear Unclear Low Low Unclear Unclear High 
Stanley 1989b Unclear Low Unclear Unclear Low Unclear High 
Sola 2018 Low Low Low Low High Low High 
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Table 4. Model fit
 
Mortality at maximal follow­up Fixed­effect model Random­effects model Inconsistency mod­
el 
Dbar 255.1 253.7 255.3 
DIC 297.9 299.2 303.1 
pD 42.8 45.5 47.75 
Any adverse events (number of people) Fixed­effect model Random­effects model Inconsistency mod­
el 
Dbar 38.89 39.75 ­
DIC 46.75 48.72 ­
pD 7.862 8.96 ­
Liver transplantation at maximal follow­up Fixed­effect model Random­effects model Inconsistency mod­
el 
Dbar 54.83 54.1 ­
DIC 64.51 65.98 ­
pD 9.684 11.88 ­
Resolution of ascites at maximal follow­up Fixed­effect model Random­effects model Inconsistency mod­
(by ultrasound) el 
Dbar 182.7 135 ­
DIC 206.4 165.3 ­
pD 23.73 30.24 ­
Other features of decompensation at maxi­ Fixed­effect model Random­effects model Inconsistency mod­
mal follow­up el 
Dbar 258 258.1 253 
DIC 293.9 294 294.7 
pD 35.89 35.92 41.71 
Length of hospital stay (days) (all admis­ Fixed­effect model Random­effects model Inconsistency mod­
sions until maximal follow­up) el 
Dbar 152.7 122.8 122.7 
DIC 173.7 147.2 147.3 
pD 20.95 24.39 24.56 
Treatment for ascites in adults with decompensated liver cirrhosis: a network meta­analysis (Review)
 








       
   
         
         
       
             
 
 
                               
             
                                           
                                     
                                           
                                             
                                           
                                               
                                           
                                           
                                                 
     
           
 
                       






Library Better health. Cochrane Database of Systematic Reviews
 
Table 4. Model fit  (Continued) 
Treatment costs Fixed­effect model Random­effects model Inconsistency mod­
el 
Dbar 4961 34.09 ­
DIC 4963 38.08 ­
pD 2.023 3.998 ­
Dbar = posterior mean of deviance
 
DIC = deviance information criteria
 
pD = effective number of parameters or leverage
 
Table 5. Effect estimates (network meta­analysis)
 
This table is too wide to be displayed in RevMan. This table can be found at: https://doi.org/10.5281/zenodo.3604602
 
The table provides the effect estimates of each pairwise comparison for the different outcomes. The top half of the table indicates the effect
 
estimates from the direct comparisons. The bottom half of the table indicates the effect estimates from the network meta­analysis. For
 
network meta­analysis, to identify the effect estimate of a comparison, say A versus B, look at the cell that occupies the row corresponding
 
to intervention A and the column corresponding to intervention B for the direct effect estimate. If that cell is empty (indicated by a '­'),
 
look at the row corresponding to intervention B and the column corresponding to intervention A. Take the inverse of this number (i.e. 1/
 
number) to arrive at the treatment effect of A versus B. For direct comparisons, this is exactly the opposite; look at the cell that occupies
 
the column corresponding to intervention A and the row corresponding to intervention B for the direct effect estimate. If that cell is empty,
 
look at the column corresponding to intervention B and the row corresponding to intervention A. Take the inverse of this number to arrive
 
at the treatment effect of A versus B. If the cell corresponding to B versus A is also missing in direct comparisons, this means that there
 
was no direct comparison.
 
Statistically significant results are shown in italics.
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Mean difference and 95% confidence 

















76.7 USD 20 3368.0 
USD 













295 USD not report­
ed 
10 440 USD Not re­
ported 






















































































































































USD = United States Dollar
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Table 7. Effect estimates (Subgroup: grade 3 ascites only)
 
This table is too wide to be displayed in RevMan. This table can be found at: https://doi.org/10.5281/zenodo.3604780.
 
The table provides the network meta­analysis effect estimates for the subgroup of grade 3 ascites only of each pairwise comparison for the
 
different outcomes. To identify the effect estimate of a comparison, say A versus B, look at the cell that occupies the row corresponding to
 
intervention A and the column corresponding to intervention B for the direct effect estimate. If that cell is empty (indicated by a '­'), look at
 
the row corresponding to intervention B and the column corresponding to intervention A. Take the inverse of this number (i.e. 1/number)
 
to arrive at the treatment effect of A versus B.
 




HR = hazard ratio; OR = odds ratio
 
Table 8. Effect estimates (Subgroup: refractory or recurrent ascites only)
 
This table is too wide to be displayed in RevMan. This table can be found at: https://doi.org/10.5281/zenodo.3604784.
 
The table provides the network meta­analysis effect estimates for the subgroup of refractory or recurrent ascites only of each pairwise
 
comparison for the different outcomes. To identify the effect estimate of a comparison, say A versus B, look at the cell that occupies the
 
row corresponding to intervention A and the column corresponding to intervention B for the direct effect estimate. If that cell is empty
 
(indicated by a '­'), look at the row corresponding to intervention B and the column corresponding to intervention A. Take the inverse of
 
this number (i.e. 1/number) to arrive at the treatment effect of A versus B.
 




HR = hazard ratio
 




Appendix 1. Search strategies
 
Database Time span Search strategy
 





























Treatment for ascites in adults with decompensated liver cirrhosis: a network meta­analysis (Review)
 








       
       
     
       
     
                   
                       
       
                         
         
   
 
                       
































17. exp animals/ not humans.sh.
 








































#3 TS=(random* OR rct* OR crossover OR masked OR blind* OR placebo* OR meta­
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1. We used the 'paracentesis plus fluid replacement' as the reference group (from 'no active intervention'), as 'paracentesis plus fluid
 
replacement' was the commonest intervention compared in the trials.
 
2. We did not perform Trial Sequential Analysis (TSA) because the risk of false positive results with Bayesian meta­analysis is probably
 
less or at least equivalent to TSA.
 
3. We used the latest guidance from the GRADE Working group (Yepes­Nunez 2019) rather than the previous guidance (Puhan 2014) for
 
presenting the 'Summary of Findings' table.
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4. The trials did not report the proportion of people with other episodes of decompensation but reported the number of episodes of
 
decompensation. Therefore, we treated this as a count outcome and used the Poisson likelihood to calculate the rate ratio.
 
5. In the absence of a protocol published prior to the start of the study, we classified the risk of bias as low for selective reporting bias only
 
when mortality, adverse events, and resolution from ascites were reported, as we anticipated these outcomes to be routinely measured
 
in clinical trials of this nature.
 
6. We used 30,000 iterations (instead of 10,000 iterations) as a minimum for burn­in of the simulation sampler used to estimate quantities
 
in the statistical models to ensure convergence of the simulation sampler.
 
7. We did not present some information such as ranking probability tables, rankograms, and surface area under the curve (SUCRA plots)
 
because of the concern about the misinterpretation of the results. We have highlighted this clearly within the text of the review along
 




We based the Methods section of this protocol on a standard Cochrane Hepato­Biliary Group template incorporating advice by the Complex
 
Reviews Support Unit for a network meta­analysis protocol (Best 2018).
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